

ReWalk Robotics Ltd.  
Form PRE 14A  
March 16, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Under Rule 14a-12

**ReWalk Robotics Ltd.**

(Name of the Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

Edgar Filing: ReWalk Robotics Ltd. - Form PRE 14A

1) Amount previously paid:

2) Form, Schedule or Registration Statement No:

3) Filing Party:

4) Date Filed:

REWALK ROBOTICS LTD.

3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel

Tel: (+972-4) 959-0123

Dear Shareholder,

You are cordially invited to attend the 2018 Annual Meeting of Shareholders (the “Meeting”) of ReWalk Robotics Ltd. to be held at 5:00 p.m. (Israel time) on Monday, April 30, 2018, at the law offices of Goldfarb Seligman & Co., Ampa Tower, 98 Yigal Alon Street, 36<sup>th</sup> floor, Tel Aviv, Israel.

The agenda for the Meeting is set forth in the accompanying Notice of 2018 Annual Meeting of Shareholders and Proxy Statement.

For the reasons set forth in the accompanying Proxy Statement, our board of directors recommends that you vote “FOR” each of the proposals on the agenda for the Meeting.

We look forward to greeting personally those of you who are able to be present at the Meeting. However, whether or not you plan to attend the Meeting, it is important that your shares be represented. Accordingly, you are kindly requested to sign, date and mail the enclosed proxy card at your earliest convenience so that it will be received no later than 24 hours before the Meeting to be validly included in the tally of ordinary shares voted at the Meeting. Detailed proxy voting instructions are provided both in the Proxy Statement and on the proxy card.

If your ordinary shares are held in “street name”, that is, in a brokerage account or by a trustee or nominee, you should complete the voting instruction card that will be sent to you in order to direct your broker, trustee or nominee how to vote your shares. You may also be able to provide such voting instructions via the Internet.

Thank you for your continued cooperation.

Very truly yours,

**Jeff Dykan**  
*Chairman of the Board of Directors*

Yokneam Ilit, Israel

March [ ], 2018

**NOTICE OF ANNUAL MEETING OF SHAREHOLDERS**

**OF**

**REWALK ROBOTICS LTD.**

3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel

Tel: (+972-4) 959-0123

To the shareholders of ReWalk Robotics Ltd.:

Notice is hereby given that the 2018 Annual Meeting of Shareholders (the “Meeting”) of ReWalk Robotics Ltd. (the “Company”) will be held at 5:00 p.m. (Israel time) on Monday, April 30, 2018, at the law offices of Goldfarb Seligman & Co., Ampa Tower, 98 Yigal Alon Street, 36<sup>th</sup> floor, Tel Aviv, Israel.

The agenda of the Meeting will be as follows:

1. To reelect the directors named in the attached Proxy Statement, each as a Class I director of the board of directors of the Company (the “Board” or the “Board of Directors”), to serve until the 2021 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999 (the “Israel Companies Law”).

2. To approve, in accordance with the requirements of the Israel Companies Law, the grant of restricted share units to our directors, at the time each director joins the Board and thereafter on an annual basis, in lieu of our current director equity compensation arrangements.

3. To approve the issuance of 16,000,000 ordinary shares in a private placement to Timwell Corporation Limited (“Timwell”), subject to the satisfaction of conditions precedent specified in the Investment Agreement between us and Timwell, as required by the Israel Companies Law and Rule 5635(b) of The NASDAQ Stock Market LLC (“Nasdaq Rule 5635(b”).

4. To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

5. To report on the business of the Company for the year ended December 31, 2017 and review the 2017 financial statements.
6. To act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.

These proposals are described more fully in the enclosed Proxy Statement, which we urge you to read in its entirety.

Only shareholders of record at the close of business on the record date of March 21, 2018 are entitled to notice of, and to vote at, the Meeting and any adjournment or postponement thereof. You are cordially invited to attend the Meeting in person.

If you are unable to attend the Meeting in person you are requested to complete, date and sign the enclosed proxy card and return it promptly in the pre-addressed envelope provided so that it is received by us at least 24 hours before the Meeting or vote by telephone or over the Internet if your voting instruction form describes such voting methods. Your proxy may be revoked at any time before it is voted if you return a later-dated proxy card or if you vote your shares in person at the Meeting if you are the record holder of the shares and can provide a copy of a certificate(s) evidencing your shares. If your shares are held in “street name,” meaning in the name of a bank, broker or other record holder, you must either direct the record holder of your shares on how to vote your shares or obtain a legal proxy from the record holder to vote the shares at the Meeting on behalf of the record holder as well as a statement from such record holder that it did not vote such shares on your behalf. Further, if you are a beneficial owner whose shares are held of record by a broker, your broker has discretionary voting authority to vote your shares only on routine matters, which at our upcoming meeting will only be the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 (Proposal Four), even if the broker does not receive voting instructions from you. Your broker does not have discretionary authority to vote on non-routine matters without instructions from you, in which case a “broker non-vote” will occur and your shares will not be voted on these matters.

Joint holders of shares should note that, pursuant to our Articles of Association, the vote of the senior of joint holders of any share who votes such share, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other registered holder(s) of such share, with seniority determined by the order in which the names of the joint holders appear in our Register of Shareholders. For the appointment of a proxy to vote shares held by joint holders to be valid, the signature of the senior of the joint holders must appear on the proxy card.

By Order of the Board of Directors,

**Jeff Dykan**  
*Chairman of the Board of Directors*

Yokneam Ilit, Israel

March [ ], 2018

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR  
THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2018**

**You are urged to mark, date, sign and promptly return the proxy card in the envelope provided to you so that if you are unable to attend the Meeting your shares can be voted. The Notice and Proxy Statement and the 2017 Annual Report are available at <http://ir.rewalk.com>.**





## EXPLANATORY NOTE

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As an emerging growth company and a smaller reporting company, we provide in this proxy statement the scaled disclosure permitted under the JOBS Act and otherwise as applicable to smaller reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our “named executive officers” or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as “golden parachute” arrangements.

Under the JOBS Act, we will remain an “emerging growth company” until the earliest of: (i) the last day of the fiscal year during which we have total annual gross revenues of \$1.07 billion or more (as adjusted every five years for inflation); (ii) the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering on September 12, 2014; (iii) the date on which we have, during the previous three-year period, issued more than \$1.0 billion in non-convertible debt; and (iv) the date on which we are deemed to be a “large accelerated filer” under the Exchange Act. We will qualify as a large accelerated filer as of the first day of the first fiscal year after we have at least \$700 million in outstanding voting and non-voting common equity held by our non-affiliates, as measured as of the last business day of the second quarter of the fiscal year. We will remain a “smaller reporting company” until the last day of the fiscal year in which we have at least \$75.0 million in outstanding voting and non-voting common equity held by our non-affiliates, as measured as of the last business day of the second quarter of the fiscal year

**TABLE OF CONTENTS**

<u>QUESTIONS AND ANSWERS ABOUT THE MEETING</u>	2
<u>DATE THESE PROXY MATERIALS ARE FIRST BEING MADE AVAILABLE</u>	6
<u>PROPOSAL ONE – ELECTION OF CLASS I DIRECTORS</u>	7
<u>CORPORATE GOVERNANCE</u>	11
<u>AUDIT COMMITTEE REPORT</u>	21
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	22
<u>DIRECTOR COMPENSATION</u>	24
<u>EXECUTIVE COMPENSATION</u>	26
<u>EQUITY COMPENSATION PLANS</u>	30
<u>EQUITY COMPENSATION PLAN INFORMATION</u>	37
<u>PROPOSAL TWO – GRANTS OF RSUs TO DIRECTORS</u>	38
<u>THE TIMWELL TRANSACTIONS</u>	40
<u>PROPOSAL THREE – APPROVAL OF THE ISSUANCE OF 16,000,000 ORDINARY SHARES IN A PRIVATE PLACEMENT TO TIMWELL, SUBJECT TO THE SATISFACTION OF CERTAIN CONDITIONS PRECEDENT, AS REQUIRED BY ISRAELI LAW AND NASDAQ RULES</u>	45
<u>PROPOSAL FOUR – REAPPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	49
<u>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</u>	51
<u>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</u>	56
<u>REVIEW OF THE COMPANY’S FINANCIAL STATEMENTS FOR 2017</u>	56
<u>PROPOSALS OF SHAREHOLDERS AT 2019 ANNUAL MEETING</u>	56
<u>OTHER BUSINESS</u>	56
<u>ADDITIONAL INFORMATION</u>	57

REWALK ROBOTICS LTD.

3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel

Tel: (+972-4) 959-0123

PROXY STATEMENT

This proxy statement (“Proxy Statement”) is being furnished to the holders of our ordinary shares, par value NIS 0.01 each, in connection with the solicitation of proxies by our Board of Directors (the “Board”) for use at the 2018 Annual Meeting of Shareholders (the “Meeting”) to be held on Monday, April 30, 2018, at 5:00 p.m. (Israel time) and at any adjournment or postponement thereof, pursuant to the accompanying Notice of Extraordinary General Meeting of Shareholders.

The agenda of the Meeting will be as follows:

1. To reelect the directors named in this Proxy Statement, each as a Class I director of the Board, to serve until the 2021 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999 (the “Israel Companies Law”).

2. To approve, in accordance with the requirements of the Israel Companies Law, the grant of restricted share units (“RSUs”) to our directors, at the time each director joins the Board and thereafter on an annual basis, in lieu of our current director equity compensation arrangements.

3. To approve the issuance of 16,000,000 ordinary shares in a private placement to Timwell Corporation Limited (“Timwell”), subject to the satisfaction of conditions precedent specified in the Investment Agreement between us and Timwell, as required by the Israel Companies Law and Rule 5635(b) of The Nasdaq Stock Market LLC (“Nasdaq Rule 5635(b”).

4. To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

Edgar Filing: ReWalk Robotics Ltd. - Form PRE 14A

5. To report on the business of the Company for the year ended December 31, 2017 and review the 2017 financial statements.

6. To act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.

Currently, we are not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, the persons designated as proxies intend to vote in accordance with their judgment on such matters.

## QUESTIONS AND ANSWERS ABOUT THE MEETING

### GENERAL

#### **Q: When and where is the Annual General Meeting of Shareholders being held?**

A: The Meeting will be held on Monday, April 30, 2018, at 5:00 p.m. (Israel time), at the law offices of Goldfarb Seligman & Co., Ampa Tower, 98 Yigal Alon Street, 36<sup>th</sup> floor, Tel Aviv, Israel.

#### **Q: Who can attend the Meeting?**

Any shareholder may attend. Please note that space limitations make it necessary to limit attendance to shareholders and one guest. Admission will be on a first-come, first-served basis. Current proof of ownership of ReWalk's shares as of the Record Date (as defined below), as well as a form of personal photo identification, must be presented in order to be admitted to the Meeting. If your shares are held in the name of a bank, broker or other holder of record, you must bring a current brokerage statement or other form of proof reflecting ownership as of the Record Date (as defined below) with you to the Meeting. No cameras, recording equipment, electronic devices, use of cell phones or other mobile devices, large bags or packages will be permitted at the Meeting.

#### **Q: Who is entitled to vote?**

A: Only holders of record of ordinary shares at the close of business on March 21, 2018 (the "Record Date") are entitled to notice of, and to vote at, the Meeting and any adjournment or postponement thereof. Each shareholder is entitled to one vote for each ordinary share owned as of the Record Date. Ordinary shares held in our treasury, which are not considered outstanding, will not be voted.

Joint holders of shares should note that, pursuant to our Articles of Association, the vote of the senior of joint holders of any share who votes such share, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other registered holder(s) of such share, with seniority determined by the order in which the names of the joint holders appear in our Register of Shareholders. For the appointment of a proxy to vote shares held by joint holders to be valid, the signature of the senior of the joint holders must appear on the proxy card.

## HOW TO VOTE YOUR SHARES

**Q: How do I vote?**

**A:** **You may vote in person.** Ballots will be passed out at the Meeting to anyone who wants to vote at the Meeting. If you choose to do so, please bring the enclosed proxy card or proof of identification. If you are a shareholder of record, meaning that your shares are held directly in your name, you may vote in person at the Meeting. However, if your shares are held in “street name” (that is, through a bank, broker or other nominee), you must first obtain a signed proxy from the record holder (that is, your bank, broker or other nominee) and vote.

**“Street name” holders may also vote by phone or through an Internet website.** If you hold your shares in “street name” (e.g., through a broker, bank or other nominee), then you should have received this Proxy Statement from the bank, broker or nominee, along with its proxy card with voting instructions (including voting by phone or through an Internet website) and instructions on how to change your vote. Thus, if you are “street name” holder, your votes will be processed based on your instructions to your bank, broker or other nominee on how to vote the ordinary shares. Because you are not a shareholder of record, you may not vote those shares directly at the Meeting unless you obtain a “legal proxy” from the bank, broker or other nominee that holds your shares directly, giving you the right to vote the shares at the Meeting.

**You may vote by mail.** Both shareholders of record and “street name” holders can do this by completing the proxy card (for shareholders of record) or voting instruction card (for “street name” holders”) and returning it in the enclosed, prepaid and addressed envelope. If you return a signed card but do not provide voting instructions, your shares will be voted as recommended by the Board.

**Q: What is the difference between holding shares as a shareholder of record and holding shares in “street name”?**  
**A: Will my shares be voted if I do not provide my proxy?**

Many ReWalk shareholders hold their shares through a bank, broker or other nominee rather than directly in their own name. As explained in this Proxy Statement, there are some distinctions between shares held of record and shares owned in “street name.”

### **Shareholders of Record**

If your shares are registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, LLC of New York, New York, you are considered, with respect to those shares, the shareholder of record. In such case, these proxy materials are being sent directly to you. As the shareholder of record, you have the right to grant your voting proxy directly to ReWalk or to vote in person at the Meeting. If you hold your shares directly in your own name and do not provide a proxy, your shares will not be voted.

### **“Street Name” Holders (Beneficial Owners)**

If your shares are held through a bank, broker or other nominee, they are considered to be held in “street name” and you are the beneficial owner. If your shares are held in street name, these proxy materials are being forwarded to you by your bank, broker or nominee which is considered, with respect to those shares, the shareholder of record. As the beneficial owner, you have the right to direct the bank, broker or nominee how to vote your shares for the Meeting. You also may attend the Meeting. However, because you are not the shareholder of record, you may not vote these shares in person at the Meeting, unless you first obtain a signed proxy from the record holder (your bank, broker or other nominee) giving you the right to vote the shares. Your bank, broker or nominee has enclosed a voting instruction card for you to use in directing the bank, broker or nominee regarding how to vote your shares.

If you are a beneficial owner whose shares are held of record by a broker, your broker has discretionary voting authority to vote your shares without your instructions only on routine matters, which at our upcoming Meeting will only be the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 (Proposal Four). Your broker does not have discretionary authority to vote on non-routine matters without instructions from you, in which case a “broker non-vote” will occur and your shares will not be voted on these matters. Thus, while your broker may vote on Proposal Four without instructions from you, your broker may not vote on Proposal One, Proposal Two or Proposal Three unless you provide instructions. In the event of a broker non-vote, the shares held by you will be included in determining the presence of a quorum at the Meeting, but are not considered “present” for purposes of voting on the proposals. It is important for a shareholder that holds ordinary shares through a bank, broker or other nominee to instruct its bank, broker or other nominee regarding how to vote its shares if the shareholder wants its shares to count



towards the vote tally for a given proposal.

3

**Q: Does ReWalk recommend I vote in advance of the Meeting?**

A: **Yes.** Even if you plan to attend the Meeting, we recommend that you vote your shares in advance so that your vote will be counted if you later decide not to attend the Meeting.

**Q: If I vote by proxy, can I change my vote or revoke my proxy?**

A: **Yes.** You may change your proxy instructions at any time prior to the vote at the Meeting. If you are a shareholder of record, you may do this by:

filing a written notice of revocation with our CFO, delivered to our address above;

delivering a timely later-dated proxy card or voting instruction form; or

attending the Meeting and voting in person (attendance at the Meeting will not cause your previously granted proxy to be revoked unless you specifically so request).

If you hold shares through a bank, broker or other nominee, you may revoke any prior voting instructions by contacting that firm or by voting in person via “legal proxy” at the Meeting.

**Q: How are my votes cast when I submit a proxy vote?**

A: When you submit a proxy vote, you appoint Jeff Dykan, Larry Jasinski and Ori Gon, or any of them, as your representative(s) at the Meeting. Your shares will be voted at the Meeting as you have instructed.

Upon the receipt of a properly submitted proxy card, which is received by 5:00 p.m. (Israel time), on April 29, 2018, which is 24 hours prior to the Meeting, and not revoked prior to the Meeting, or which is presented to the chairperson at the Meeting, the persons named as proxies will vote the ordinary shares represented thereby at the Meeting in accordance with the Board’s recommendations as indicated in the instructions outlined on the proxy card.

**Q: What does it mean if I receive more than one proxy card?**

A:

Edgar Filing: ReWalk Robotics Ltd. - Form PRE 14A

It means that you have multiple accounts at the transfer agent or with brokers. Please sign and return all proxy cards to ensure that all of your shares are voted.

## **ABOUT THE VOTING PROCEDURES AT THE MEETING**

### **Q: What constitutes a quorum?**

In order for us to conduct business at the Meeting, two or more shareholders must be present, in person or by proxy, A: representing at least 33-1/3% of the ordinary shares outstanding as of the Record Date. This is referred to as a quorum.

Ordinary shares represented in person or by proxy (including broker non-votes and shares that abstain or do not vote with respect to one or more of the matters to be voted upon) will be counted for purposes of determining whether a quorum exists. As discussed further above, a “broker non-vote” occurs when a bank, broker or other holder of record holding shares for a beneficial owner attends the Meeting but does not vote on a particular proposal because that holder does not have discretionary voting power for that particular item and has not received instructions from the beneficial owner. Abstentions and broker non-votes will be counted as present in determining if a quorum is present.

### **Q: What happens if a quorum is not present?**

If a quorum is not present, the Meeting will be adjourned to the same day at the same time the following week, or A: to such day and at such time and place as the Chairman of the meeting may determine with the consent of the holders of a majority of the shares present in person or by proxy and voting on the question of adjournment.

### **Q: How will votes be counted?**

A: Each outstanding ordinary share is entitled to one vote. Our Articles of Association do not provide for cumulative voting.

Each of the proposed resolutions requires the affirmative vote of a simple majority of our ordinary shares voted in person or by proxy at the Meeting on the proposal. Abstentions and broker non-votes will not be treated as either a vote “**FOR**” or “**AGAINST**” the matter for Proposal One, Proposal Two and Proposal Three. Broker non-votes will not be counted as present and are not entitled to vote on Proposal One, Proposal Two and Proposal Three. Because brokers have discretionary authority to vote on Proposal Four, broker non-votes will be counted as present and are entitled to vote on Proposal Four. Abstentions will not be treated as either a vote “**FOR**” or “**AGAINST**” the matter for Proposal Four.

### **Q: How will my shares be voted if I do not provide instructions on the proxy card?**

A: If you are the record holder of your shares and do not specify on your proxy card how you want to vote your shares, your shares will be voted in favor of the proposals in accordance with the recommendation of the Board:

1.a. **“FOR”** the reelection of Mr. Jeff Dykan as a Class I director of the Board, to serve until the 2021 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law.

1.b. **“FOR”** the reelection of Mr. Yasushi Ichiki as a Class I director of the Board, to serve until the 2021 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law.

1.c. **“FOR”** the reelection of Mr. Peter Wehrly as a Class I director of the Board, to serve until the 2021 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law.

2. **“FOR”** the grant of RSUs to our directors, at the time each director joins the Board and thereafter on an annual basis, in lieu of our current director equity compensation arrangements.

3. **“FOR”** the approval of the issuance of 16,000,000 ordinary shares in a private placement to Timwell, subject to the satisfaction of conditions precedent specified in the Investment Agreement between us and Timwell, as required by the Israel Companies Law and Nasdaq Rule 5635(b).

4. **“FOR”** the approval of the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as ReWalk’s independent registered public accounting firm for the year ending December 31, 2018 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

The named proxies will act in accordance with the best judgment of the named proxies on any other matters properly brought before the annual meeting and any postponement(s) or adjournment(s) thereof.

## **HOW TO FIND VOTING RESULTS**

### **Q: Where do I find the voting results of the Meeting?**

A: We plan to announce preliminary voting results at the Meeting. The final voting results will be reported following the Meeting on the “Investors” portion on our website at [www.rewalk.com](http://www.rewalk.com) and in a Current Report on Form 8-K that will be filed with the U.S. Securities and Exchange Commission (the “SEC”) within four business days after the Meeting.

## **SOLICITATION OF PROXIES**

### **Q: Who will bear the costs of solicitation of proxies for the Meeting?**

A: ReWalk will bear the costs of solicitation of proxies for the Meeting. In addition to solicitation by mail, directors, officers and employees of ReWalk may solicit proxies from shareholders by telephone, in person or otherwise. Such directors, officers and employees will not receive additional compensation, but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. Brokers, nominees, fiduciaries and other

custodians have been requested to forward soliciting material to the beneficial owners of ordinary shares held of record by them, and such custodians will be reimbursed by ReWalk for their reasonable out-of-pocket expenses. ReWalk may also retain an independent contractor to assist in the solicitation of proxies. If retained for such services, the costs will be paid by us.

## **POSITION STATEMENTS**

### **Q: Can a shareholder express an opinion on a proposal prior to the Meeting?**

In accordance with the Israel Companies Law and regulations promulgated thereunder, any ReWalk shareholder may submit a position statement on its behalf, expressing its position on an agenda item for the Meeting, to ReWalk A:Robotics Ltd., 3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel, Attention: Chief Financial Officer, or by facsimile to +972-4-959-0125, no later than April 20, 2018. Position statements must be in English and otherwise must comply with applicable law. We will make publicly available any valid position statement that we receive.

## **DATE THESE PROXY MATERIALS ARE FIRST BEING MADE AVAILABLE**

We are first making available this Proxy Statement and accompanying materials to shareholders on or about March [ ], 2018. This Proxy Statement and our 2017 Annual Report are also available at <http://ir.rewalk.com>. Information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Statement and is not incorporated by reference herein.

## **MATTERS SUBMITTED TO SHAREHOLDERS**

### **PROPOSAL ONE**

#### **ELECTION OF CLASS I DIRECTORS**

Our Board currently consists of eight directors. Our Articles of Association provide that our Board may consist of not less than five and not more than thirteen directors.

Under our Articles of Association, our directors (other than our external directors, if any, as discussed below) are divided into three classes. Class I currently consists of three directors, Class II currently consists of two directors and Class III currently consists of two directors. At each annual meeting of our shareholders, directors are elected or reelected for a term of office that expires at the third annual meeting following such election or reelection, such that, each year, the term of office of one class of directors expires.

In addition to the directors who are members of our three classes of directors, Dr. John William Poduska serves as an at-large member of our Board. Dr. Poduska previously served as one of our external directors, and became an at-large director as described below under “Opt-Out of Certain Israel Companies Law Requirements”.

Each director serves throughout the term of his or her class (except, in the case of Dr. Poduska, who will serve until the annual general meeting of shareholders in 2019), except in the event of his or her earlier death, resignation, removal or termination otherwise. The term of each of our Class I directors, Mr. Jeff Dykan, Mr. Yasushi Ichiki and Mr. Peter Wehrly, expires at the Meeting. Our Class II directors, Mr. Larry Jasinski and Ms. Deborah DiSanzo, will hold office until the annual meeting of our shareholders in 2019. Our Class III directors, Mr. Wayne B. Weisman and Mr. Aryeh (Arik) Dan, will hold office until the annual meeting of our shareholders in 2020.

Except as indicated herein, there are no arrangements or understandings between any director or nominee for directorship and any other person pursuant to which such director or nominee was selected as director or nominee.

Upon recommendation of our nominating and corporate governance committee, our Board has nominated Mr. Jeff Dykan, Mr. Yasushi Ichiki and Mr. Peter Wehrly as Class I directors to serve until the 2021 annual general meeting of



shareholders. Each nominee has consented to being named in this Proxy Statement and to serve if elected and has advised us that he has the qualifications and time required for the performance of his duties as a director, and that there are no legal restrictions preventing him from assuming such office.

## **Director Nominees**

### ***Nominees for Election to the Board as Class I Directors to Serve Until the 2021 Annual General Meeting of Shareholders***

*Jeff Dykan, 59*, has served on our Board since 2006 and has been the Chairman of our Board since 2009. He was appointed by our shareholder SCP Vitalife Partners II L.P. Mr. Dykan has been a director of SCP Vitalife GP, the corporate general partner of the common general partner of each of SCP Vitalife Partners II L.P. and its successor fund SCP Vitalife Partners (Israel) II L.P., since 2002 and 2007, respectively. Prior to joining Vitalife, from 2001 to 2002, Mr. Dykan was the Chairman and Chief Executive Officer of BitBand Inc., formerly a provider of content management and delivery systems, specializing in video on demand for IPTV. Mr. Dykan is a member of the American Institute of CPAs and holds a B.Sc. in accounting and management and an M.B.A. in computer applications, both from New York University. We believe that Mr. Dykan's extensive knowledge of corporate finance, securities and investments and his years of acting in management roles provide him the qualifications and skills to serve as a member of our Board.

*Yasushi Ichiki, 50*, has served on our Board since 2014. He was appointed by our shareholder Yaskawa Electric Corporation. Mr. Ichiki has been the Manager of the Corporate Planning Group, Corporate Planning Division, of Yaskawa Electric Corporation since May 2014. Previously, from February 2010 to April 2014, he served as the General Manager of Corporate Planning, Robotics Division of Yaskawa Europe GmbH. Mr. Ichiki holds a B.A. from Yamaguchi University, Japan. We believe that Mr. Ichiki's management experience and his expertise in the development and marketing of robotics and power electronics technology provide him the qualifications and skills to serve as a member of our Board.

*Peter Wehrly, 59*, has served on our Board since April 2016. Mr. Wehrly previously served in multiple senior roles at Covidien plc, including Group President of Developed Markets and Group President of Respiratory & Monitoring Solutions and Vascular Therapies from 2009 until 2015, during which Covidien was a public company listed on the New York Stock Exchange. Prior to joining Covidien, Mr. Wehrly served as President and Chief Executive Officer at Medingo Ltd., an Israel-based company, from 2008 to 2009. From 2000 to 2008 he held senior executive-level roles at Medtronic Spinal and Biologics in Memphis, Tennessee, where he oversaw the global market expansion of Medtronic's core spinal fusion therapies, minimal access technologies, motion-sparing devices and biologic technologies. Prior to that, Mr. Wehrly spent 17 years at DePuy, a division of Johnson & Johnson, and most recently served as DePuy's Sports Medicine Division President from 1997 to 2000. Throughout his career at various companies, Mr. Wehrly headed regional strategies to gain regulatory approval and reimbursement for new technologies in Europe, Japan, Australia, New Zealand, the United States and Canada. In addition, since 2012 Mr. Wehrly has been a director of Non Linear Technologies Ltd. Since April 2016, Mr. Wehrly has served as the President, CEO and a director of PQ Bypass, Inc, a start-up company focused on long lesion technologies for PAD. Mr. Wehrly also serves on the board of Synaptive Medical, a Toronto based private company which primarily focuses on leading edge technology in the neuro/cranial marketplace, and was chairman of its board until January 2018. Mr. Wehrly holds a Bachelor of Science in Management from Ball State University in Muncie, Indiana and has been a member of a number of community boards. We believe that Mr. Wehrly's leadership as an executive officer of various healthcare companies and his extensive experience in gaining regulatory approvals and reimbursement for new technologies provide him the qualifications and skills to serve as a member of our Board.

If elected at the Meeting, each nominee will serve until the 2020 annual meeting of our shareholders and until his respective successor has been duly elected and qualified, or until his office is vacated in accordance with our Articles of Association or the Israel Companies Law.

## **Proposed Resolutions**

You are requested to adopt the following resolutions:

“1.a. RESOLVED, that Mr. Jeff Dykan be reelected as a Class I director, to serve until the 2021 annual meeting of shareholders and until his successor has been elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999”;

“1.b. RESOLVED, that Mr. Yasushi Ichiki be reelected as a Class I director, to serve until the 2021 annual meeting of shareholders and until his successor has been elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999”; and

“1.c. RESOLVED, that Mr. Peter Wehrly be reelected as a Class I director, to serve until the 2021 annual meeting of shareholders and until his successor has been elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999”.

## Vote Required

The affirmative vote of a majority of our ordinary shares voted in person or by proxy at the Meeting on each of the foregoing resolutions is required to adopt such resolutions.

## Board Recommendation

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “**FOR**” THE ADOPTION OF EACH OF THE FOREGOING RESOLUTIONS.

## Continuing Directors

### *Class II Directors Continuing in Office Whose Terms Expire at the 2019 Annual General Meeting of Shareholders*

Set forth below is a list of our directors continuing in office until the 2019 annual general meeting of shareholders, together with certain biographical information, including their ages as of the date of this Proxy Statement:

*Larry Jasinski, 60*, has served as our Chief Executive Officer and as a member of our board since February 2012. From 2005 until 2012, Mr. Jasinski served as the President and Chief Executive Officer of Soteira, Inc., a company engaged in development and commercialization of products used to treat individuals with vertebral compression fractures, which was acquired by Globus Medical in 2012. From 2001 to 2005, Mr. Jasinski was President and Chief Executive Officer of Cortek, Inc., a company that developed next-generation treatments for degenerative disc disease, which was acquired by Alphatec in 2005. From 1985 until 2001, Mr. Jasinski served in multiple sales, research and development, and general management roles at Boston Scientific Corporation. Mr. Jasinski has served on the board of directors of Massachusetts Bay Lines since 2015 and of LeMaitre Vascular, Inc. since 2003. Mr. Jasinski holds a B.Sc. in marketing from Providence College and an MBA from the University of Bridgeport. We believe that Mr. Jasinski’s successful leadership and executive experience, along with his extensive knowledge of the medical devices industry and research and development, provide him the qualifications and skills to act as a member of our Board.

*Deborah DiSanzo, 58*, has served on our Board since September 2015. Since September 2015, Ms. DiSanzo has been the General Manager of IBM Watson Healthcare. From 2012 to 2014 Ms. DiSanzo was Chief Executive Officer of

Philips Healthcare, a medical imaging, patient monitoring systems and resuscitation products manufacturer controlled by Koninklijke Philips N.V. (NYSE:PHG). Previously at Philips Healthcare, she was CEO of Patient Care and Clinical Informatics (PCCI), CEO of Healthcare Informatics and Patient Monitoring and General Manager of Patient Monitoring. Ms. DiSanzo joined Philips in 2001 when Philips acquired Agilent's Healthcare Solutions Group. She holds a B.S. from Merrimack College and an M.B.A. from Babson College. We believe that Ms. DiSanzo's expertise in the healthcare sphere and her understanding of the needs of consumers of healthcare products and services provide her the qualifications and skills to serve as a member of our Board.

***Class III Directors Continuing in Office Whose Terms Expire at the 2020 Annual General Meeting of Shareholders***

Set forth below is a list of our directors continuing in office until the 2020 annual general meeting of shareholders, together with certain biographical information, including their ages as of the date of this Proxy Statement:

*Wayne B. Weisman, 62*, has served on our Board since 2009, and as a member of our audit committee since the end of December 2017. He was appointed by our shareholder SCP Vitalife Partners II L.P. Since 2007, Mr. Weisman has been a director of SCP Vitalife GP, the corporate general partner of the common general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel) II L.P. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife. Mr. Weisman is Chairman of Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain. He also serves on the board of a number of private companies, including Echo360 Inc. Mr. Weisman previously served on the board of directors of each of EndoSpan Ltd. from 2009 to 2015, Ivenix, Inc. from 2011 to 2015 and Pocared Diagnostics Ltd. from 2007 to 2015. He is the vice chairman of the boards of trustees of Young Scholars School. He is also an advisory board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University. Mr. Weisman holds a B.A. from the University of Pennsylvania and a J.D. from the University of Michigan Law School. We believe that Mr. Weisman's leadership as a director of various pharmaceutical and healthcare companies and his extensive experience serving as a director on other boards provide him the qualifications and skills to serve as a member of our Board.

*Aryeh (Arik) Dan, 59*, has served on our Board since 2013. He was appointed by our shareholder Yaskawa Electric Corporation, a manufacturer of motion controllers, switches, industrial robots and other automation products. He has served as the President and Chief Executive Officer of Yaskawa Europe Technology since 2005. Mr. Dan holds a B.Sc. in aeronautical engineering from the Technion—Israel Institute of Technology and completed studies in the M.B.A. research program at Keio University, Japan. We believe that Mr. Dan's leadership experience and his expertise in robotics technology and research and development provide him with the qualifications and skills to serve as a member of our Board.

***Other Director Continuing in Office Whose Term Expires on December 15, 2020***

*Dr. John William Poduska, 80*, has served on our Board since 2014. Dr. Poduska currently serves as a director of EXA Corporation (NASDAQ: EXA), a developer and provider of simulation software systems, where he serves as chairman of the compensation committee and a member of the nominating and corporate governance committee. He also serves as a director on the boards of a number of privately-held companies. Dr. Poduska also served as a director of Novell, Inc. until 2011 and of Anadarko Petroleum Corporation and Safeguard Scientifics, Inc. until 2009. Dr.

Poduska was the Chairman of Advanced Visual Systems Inc., a provider of visualization software, from January 1992 to December 2001. From December 1989 until December 1991, Dr. Poduska was President and Chief Executive Officer of Stardent Computer Inc., a computer manufacturer. From December 1985 until December 1989, Dr. Poduska served as Chairman and Chief Executive Officer of Stellar Computer Inc., a computer manufacturer he founded which is the predecessor of Stardent Computer Inc. Prior to founding Stellar Computer, Inc., Dr. Poduska founded Apollo Computer Inc. and Prime Computer, Inc. Dr. Poduska holds a Sc.D. from MIT and an Honorary Doctorate of Humane Letters from Lowell University. We believe that Dr. Poduska's varied director experience, both in private and public companies, his expertise in computer engineering and his familiarity with developing companies equip him with the qualifications and skills to serve as a member of our Board.

## **CORPORATE GOVERNANCE**

### **Opt-Out of Certain Israel Companies Law Requirements**

As an Israeli company, we are required to comply with the requirements of the Israel Companies Law and the regulations promulgated thereunder. Until recently, our Board was required to include at least two “external directors” as defined under the Israel Companies Law. In addition, we were required to comply with certain requirements under the Israel Companies Law regarding the composition of our audit committee and compensation committee, including requirements relating to the inclusion and role of the external directors on such committees. Pursuant to regulations promulgated relatively recently under the Israel Companies Law, however, we— as a company that does not have a controlling shareholder, and that complies with the United States securities laws and the corporate governance rules of Nasdaq— are permitted to “opt out” of the requirement to appoint external directors as well as the above requirements related to the composition of the audit committee and the compensation committee.

Dr. Poduska and Glenn Muir previously served as our external directors. As disclosed in a Current Report on Form 8-K we filed with the SEC on December 27, 2017, Mr. Muir resigned from the Board and all committees of the Board effective December 29, 2017. Mr. Muir also served on each of the audit committee (of which he was the chairman), compensation committee and nominating and corporate governance committee, and satisfied the standards of a “financial expert” under the rules of the SEC. As a result of Mr. Muir’s resignation, Dr. Poduska was the only member of our Board who satisfied the requirements of an external director under the Israel Companies Law. In addition, our audit committee did not have a chair who was an external director.

Following Mr. Muir’s resignation, our Board determined that opting out of the requirements under the Israel Companies Law regarding the appointment of external directors and the composition of our audit committee and compensation committee would reduce our administrative and financial burden and provide greater flexibility in attracting highly-qualified directors, while maintaining appropriate corporate governance standards; accordingly, on February 8, 2018, we opted out of such requirements. As a result, our Board is no longer required to include two external directors, and our audit committee and compensation committee do not need to comply with certain committee composition requirements under the Israel Companies Law. Following our opting-out of such requirements, Dr. Poduska continues to serve as an at-large member of our Board and not as an external director or a member of any of Class I, Class II or Class III.

### **Director Independence**



Our Board has determined that all of our directors, other than Larry Jasinski, our Chief Executive Officer and Yasushi Ichiki, a Yaskawa appointee, are independent under NASDAQ listing standards. Furthermore, our Board also determined that each of the audit committee, compensation committee, and nominating and corporate governance committee is comprised of independent directors under the applicable NASDAQ listing standards and rules and regulations of the SEC. In making its determinations regarding independence, the Board carefully reviewed the categorical tests enumerated in the NASDAQ independence definition, as well as the individual circumstances of each director with regard to each director's business and personal activities as they may relate to the Company and our management.

*Nasdaq Listing Standards*

The NASDAQ definition of “independent director” includes a series of objective tests. Specifically, a director is deemed independent under the NASDAQ rules if such director is not an executive officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company’s Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Generally, the following persons are not considered independent, among others:

a director who is, or at any time during the past three years was, employed by the company;

a director who accepted or who has a family member who accepted any compensation from the company in excess of \$120,000 during any period of twelve consecutive months within the three years preceding the determination of independence, other than compensation for board or board committee service, compensation paid to a family member who is an employee (other than an executive officer) of the company, or benefits under a tax-qualified retirement plan, or non-discretionary compensation;

a director who is a family member of an individual who is, or at any time during the past three years was, employed by the Company as an executive officer;

a director who is, or has a family member who is, a partner in, or a controlling shareholder or an executive officer of, any organization to which the Company made, or from which the Company received, payments for property or services in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenues for that year, or \$200,000, whichever is more, other than the following: (i) payments arising solely from investments in the Company’s securities; or (ii) payments under non-discretionary charitable contribution matching programs;

a director who is, or has a family member who is, employed as an executive officer of another entity where at any time during the past three years any of the executive officers of the Company serve on the compensation committee of such other entity; and

a director who is, or has a family member who is, a current partner of the Company’s outside auditor, or was a partner or employee of the Company’s outside auditor who worked on the Company’s audit at any time during any of the past three years.

**Audit Committee**

We have a separately designated standing audit committee. The audit committee consists of Mr. Peter Wehrly, along with Dr. John William Poduska and Wayne Weisman. The audit committee holds a minimum of four meetings per year, and will meet more frequently as circumstances require. The audit committee met five times during the year ended December 31, 2017.

***Israel Companies Law Requirements***

Under the Israel Companies Law, we are required to appoint an audit committee. As discussed above under “Opt-Out of Certain Israel Companies Law Requirements”, on February 8, 2018, we opted out of certain Israel Companies Law requirements, including certain requirements as to the composition of our audit committee.

### *Nasdaq Listing Standards and SEC Requirements*

Under the NASDAQ corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. Additionally, we must state whether any members of the audit committee qualifies as an “audit committee financial expert” under Item 407(d) of Regulation S-K as promulgated by the SEC.

All members of the audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ corporate governance rules. As described above under “Opt-Out of Certain Israel Companies Law Requirements”, effective December 29, 2017, Glenn Muir resigned from our Board and all the Board committees on which he served, including the audit committee. Mr. Glenn Muir also served as the chair of the audit committee. Following Mr. Muir’s resignation we appointed Mr. Weisman to serve as a member of the audit committee. The Board determined that Mr. Weisman satisfies the applicable Nasdaq audit committee independence requirements and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and is financially literate for purposes of Nasdaq listing standards. The Board also determined that Mr. Weisman meets the financial sophistication requirements of Nasdaq Rule 5605(c). Since December 29, 2017, our audit committee has not had an “audit committee financial expert.” We intend as soon as possible to appoint a new member of the audit committee who satisfies the “audit committee financial expert” requirements under the rules of the SEC and who will serve as the chair of the audit committee. Currently, our audit committee members include the principal of an investment fund with experience as a director on both private and public companies, a former CEO with senior-level experience at various biotechnology and pharmaceutical companies and the founder of several private companies who also possesses diverse director experience. The Board currently believes that these skillsets provide sufficient expertise for this committee to be able to serve and function effectively for the purpose for which it is intended.

Each of the members of the audit committee is “independent” as such term is defined under the NASDAQ corporate governance rules and under Rule 10A-3(b)(1) promulgated under the Exchange Act, which is different from the general test for independence of board members and members of other committees.

### *Audit Committee Role*

Our Board has adopted an audit committee charter that sets forth the responsibilities of the audit committee consistent with the rules of the SEC and the NASDAQ corporate governance rules, as well as the requirements for such committee under the Israel Companies Law, including the following:

overseeing our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the Board in accordance with Israeli law;

reviewing regularly the senior members of the independent auditor's team, including the lead audit partner and reviewing partner;

pre-approving the terms of audit, audit-related and permitted non-audit services provided by the independent registered public accounting firm for pre-approval by our Board;

recommending the engagement or termination of the person filling the office of our internal auditor;

reviewing periodically with management, the internal audit and the independent registered public accounting firm the adequacy and effectiveness of the Company's internal control over financial reporting; and

reviewing with management and the independent registered public accounting firm the annual and quarterly financial statements of the Company prior to filing with the SEC.

The charter of the audit committee is available at <http://ir.rewalk.com>. Information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Statement and is not incorporated by reference herein.

The audit committee provides assistance to our Board in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control over financial reporting and legal compliance. Specifically, the audit committee pre-approves the services performed by our independent registered public accounting firm and reviews the firm's reports regarding our accounting practices and systems of internal control over financial reporting. The audit committee also oversees the audit efforts of our independent registered public accounting firm and takes those actions that it deems necessary to satisfy itself that such accountants are in fact independent of management.

Under the Israel Companies Law, the audit committee is responsible for:

determining whether there are deficiencies in the business management practices of our Company and making recommendations to our Board to improve such practices;

determining whether to approve certain related party transactions, and classifying transactions in which a controlling shareholder has a personal benefit or other interest as significant or insignificant (which affects the required approvals) (see “—Approval of Related Party Transactions under Israeli Law”);

examining our internal controls and internal auditor's performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities, and in certain cases approving the annual work plan of our internal auditor;

examining the scope of our auditor's work and compensation and submitting a recommendation with respect thereto to our Board or shareholders, depending on which of them is considering the appointment of our auditor; and

establishing procedures for the handling of employees' complaints as to the deficiencies in the management of our business and the protection to be provided to such employees.

The audit committee may not approve any actions requiring its approval unless at the time of the approval a majority of the committee's members are present. See “—Approval of Related Party Transactions under Israeli Law.”

## **Compensation Committee**

We have a separately designated standing compensation committee. The compensation committee consists of Dr. John William Poduska and Mr. Aryeh (Arik) Dan. Glenn Muir served as a member the nominating and corporate governance committee until his resignation from the committee effective December 29, 2017. Dr. John William Poduska serves as the chair of the compensation committee. The compensation committee meets as circumstances require, and held four meetings in 2017. Under its charter, the compensation committee may ask members of management to attend meetings and provide pertinent information as needed. However, any person forbidden to serve as a member of the committee under the Israel Companies Law may not attend committee meetings unless to present on a particular topic as determined by the committee. The CEO may not be present during voting or deliberation on his compensation.

## ***Israel Companies Law Requirements***

Under the Israel Companies Law, the board of directors of a public company must appoint a compensation committee. As discussed above under “Opt-Out of Certain Israel Companies Law Requirements”, on February 8, 2018, we opted out of certain Israel Companies Law requirements, including certain requirements as to the composition of our compensation committee.

The duties of the compensation committee include the recommendation to the company’s board of directors of a policy regarding the terms of engagement of directors and of specified members of senior management, which we refer to as a compensation policy. That compensation policy must be adopted by the company’s board of directors, after considering the recommendations of the compensation committee, and must then be approved by the company’s shareholders, which approval requires a Special Approval for Compensation (as defined below under “—Approval of Related Party Transactions under Israeli Law—Fiduciary Duties of Directors and Executive Officers”). Our Board adopted a compensation policy, which our shareholders subsequently approved at the extraordinary general meeting of our shareholders held on December 15, 2014. Our shareholders approved amendments to our compensation policy at the annual general meetings of our shareholders held on December 3, 2015, May 24, 2016 and June 27, 2017 (as amended, the “Compensation Policy”).

The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including compensation, benefits, exculpation, insurance and indemnification. The compensation policy must take into account certain factors, including advancement of the company’s objectives, the company’s business plan and its long-term strategy, and creation of appropriate incentives. It must also consider, among other things, the company’s risk management, size and the nature of its operations. The compensation policy must include certain principles, such as the following: a link between variable compensation and long-term performance and measurable criteria; the relationship between variable and fixed compensation; and the minimum



holding or vesting period for variable, equity-based compensation. We believe that our Compensation Policy satisfies these requirements.

The compensation committee is responsible for (a) recommending the compensation policy to our Board for its approval (and subsequent approval by our shareholders) and (b) duties related to the Compensation Policy and to the compensation of our directors and senior management, including:

reviewing and making recommendations regarding our Compensation Policy at least every three years;

recommending to the Board periodic updates to the Compensation Policy;

assessing implementation of the  
Compensation Policy;

approving compensation terms of executive officers, directors and employees affiliated with controlling shareholders;  
and

exempting certain compensation arrangements from the requirement to obtain shareholder approval under the Israel Companies Law.

### *Nasdaq Listing Standards*

Under the NASDAQ corporate governance rules, we are required to maintain a compensation committee consisting of at least two independent directors. Each of the members of the compensation committee is required to be independent under the NASDAQ listing standards relating to compensation committee members, which are different from the general test for independence of board and members of other committees. In assessing independence, the Board considered all factors specifically relevant to determining whether a director has a relationship to the Company which is material to that director's ability to be independent from management in connection with the duties of a compensation committee member and determined that each of the members of the compensation committee satisfies those requirements.

### *Compensation Committee Role*

Our Board has adopted a compensation committee charter setting forth the responsibilities of the committee, which include:

reviewing and approving the granting of options and other incentive awards under the Company's equity compensation plans to the extent such authority is delegated by our Board;

recommending the Company's compensation policy and reviewing that policy from time to time both with respect to the CEO and other office holders and generally, including to assess the need for periodic updates;

reviewing and approving corporate goals relevant to the compensation of the CEO and other officers and evaluating the performance of the CEO and other officers; and

reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors.

The charter of the compensation committee is available at <http://ir.rewalk.com>. Information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Statement and is not incorporated by reference herein.

Subject to applicable law, the compensation committee may delegate its authority to subcommittees established from time to time by the committee. Such subcommittees shall consist of one or more members of the committee or the board and shall report to the committee. The compensation committee is authorized to retain and terminate compensation consultants, legal counsel or other advisors to the committee and to approve the engagement of any such consultant, counsel or advisor, to the extent it deems necessary or appropriate after specifically analyzing the independence of any such consultant retained by the compensation committee.

*Compensation Consultant*

The compensation committee has authority to retain compensation consulting firms to assist it in the evaluation of executive officer and employee compensation and benefit programs. The compensation committee has retained Radford Surveys and Consulting (“Radford”) as its independent compensation advisor. Radford provides an objective perspective as to the reasonableness of our executive compensation programs and practices and their effectiveness in supporting our business and compensation objectives. During 2017, Radford advised the compensation committee with respect to individual pay decisions with respect to our executive officers and assisted us in developing a proposal for shareholder approval of the Equity Exchange Program and in structuring the execution of the program consistent with the terms of such proposal after it received the requisite shareholder approval.

While Radford regularly consults with management in performing work requested by the compensation committee, it did not perform any separate additional services for management. The compensation committee has assessed the independence of Radford pursuant to applicable SEC rules and concluded that no conflict of interests exists that would prevent Radford from independently representing the compensation committee.

### **Nominating and Corporate Governance Committee**

The nominating and corporate governance committee consists of Mr. Jeff Dykan and Mr. Aryeh (Arik) Dan. Glenn Muir served as a member the nominating and governance committee until his resignation from the committee effective December 29, 2017. Mr. Jeff Dykan serves as the chair of the nominating and governance committee. The nominating and governance committee meets as circumstances require, and held one meeting in 2017. Our Board has adopted a nominating and corporate governance committee charter that sets forth the responsibilities of the nominating and corporate governance committee, which include:

overseeing and assisting our board in reviewing and recommending nominees for election as directors;

reviewing and evaluating recommendations regarding management succession;

assessing the performance of the members of our board; and

establishing and maintaining effective corporate governance policies and practices, including, but not limited to, developing and recommending to our Board a code of conduct.

The nominating and corporate governance committee considers proposals from a number of sources, including recommendations for nominees from shareholders submitted upon written notice to the chairman of the nominating and corporate governance committee, c/o ReWalk Robotics Ltd., 3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel 2069203. When considering a person to be recommended for nomination as a director, the nomination and governance committee evaluates, among other factors, experience, accomplishments, education, skills, personal and professional integrity, diversity of the Board and the candidate's ability to devote the necessary time for service as a director (including directorships and other positions held at other corporations and organizations).

The nominating and corporate governance committee has no specific policy on director diversity. However, the Board reviews diversity of viewpoints, background, experience, accomplishments, education and skills when evaluating nominees. The Board believes that such diversity is important because it provides varied perspectives and promotes active and constructive discussion among Board members and between the Board and management, resulting in more

effective oversight of management's formulation and implementation of strategic initiatives. The Board believes this diversity is demonstrated in the range of experiences, qualifications and skills of the current members of the Board. Additionally, if at the time of election of a director all of the members of the Board are of the same gender, the director to be elected must be of the other gender. In the Board's executive sessions and in annual performance evaluations conducted by the Board and its committees, the Board from time to time considers whether the Board's composition promotes a constructive and collegial environment. In determining whether an incumbent director should stand for reelection, the nominating and corporate governance committee considers the above factors, as well as that director's personal and professional integrity, attendance, preparedness, participation and candor and other relevant factors as determined by the Board.

The charter of the nominating and corporate governance committee is available at <http://ir.rewalk.com>. Information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Statement and is not incorporated by reference herein.

## **Shareholder Communications with the Board**

The Board recommends that shareholders initiate any communications with the Board in writing and send them care of our Chief Financial Officer at the following address: 3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel. This centralized process will assist the Board in reviewing and responding to shareholder communications in an appropriate manner. The name of any specific intended Board recipient should be noted in the communication. Our Chief Financial Officer will forward such correspondence only to the intended recipients; however, prior to forwarding any correspondence our Chief Financial Officer will review such correspondence and, in his or her discretion, not forward certain items if they are deemed of a commercial or frivolous nature or otherwise inappropriate for the Board's consideration. In such cases, some of that correspondence may be forwarded elsewhere in the Company for review and possible response.

Any employee may make confidential, anonymous submissions of concerns regarding questionable accounting or auditing matters and may communicate directly with the chairman of the audit committee by letter to the above address, marked for the attention of the chairman, or by leaving a telephonic message on a dedicated employee hotline. Any written communication received from any interested party, including employees, regarding accounting, internal accounting controls or auditing matters are processed in accordance with procedures adopted by the audit committee.

## **Approval of Related Party Transactions Under Israeli Law**

### ***Disclosure of Personal Benefits or Other Interests of an Office Holder and Approval of Certain Transactions***

The Israel Companies Law requires that an office holder promptly disclose to the board of directors any personal benefit or other interest that he or she may have, and all related material information or documents, concerning any existing or proposed transaction with the company. A personal benefit or other interest includes the individual's own benefit or other interest and, in some cases, a personal benefit or other interest of such person's relative or an entity in which such individual, or his or her relative, is a 5% or greater shareholder, director or general manager, or in which he or she has the right to appoint at least one director or the general manager, but does not include a personal benefit or other interest stemming only from ownership of our shares.

If an office holder has a personal benefit or other interest in a transaction, approval by the board of directors is required for the transaction. Once an office holder has disclosed his or her personal benefit or other interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of duty of loyalty. A company may not, however, approve a transaction or action unless it is in the best

interests of the company, or if the office holder is not acting in good faith.

Special approval is required for an extraordinary transaction, which under the Israel Companies Law is defined as any of the following:

a transaction other than in the ordinary course of business;

a transaction that is not on market terms; or

a transaction that may have a material impact on a company's profitability, assets or liabilities.

An extraordinary transaction in which an office holder has a personal benefit or other interest requires approval first by the company's audit committee and subsequently by the board of directors. The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director requires approval first by the company's compensation committee, then by the company's board of directors and, if such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company's compensation policy or if the office holder is the Chief Executive Officer (apart from a number of specific exceptions), then such arrangement is subject to shareholder approval by a simple majority, which must also include at least a majority of the shares voted by all shareholders who are neither controlling shareholders nor have a personal benefit or other interest in such compensation arrangement (alternatively, in addition to a simple majority, the total number of shares voted against the compensation arrangement by non-controlling shareholders and shareholders who do not have a personal benefit or other interest in the arrangement may not exceed 2% of our outstanding shares). We refer to this as the Special Approval for Compensation. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by a simple majority, in that order, and under certain circumstances, a Special Approval for Compensation.

Generally, a person who has a personal benefit or other interest in a matter that is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless the chairman of the board of directors or the audit committee (as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. If a majority of the members of the board of directors or the audit committee (as applicable) have a personal benefit or other interest in the approval of a transaction, then all directors may participate in discussions of the board of directors or the audit committee (as applicable) on such transaction and in the voting, but shareholder approval is also required for such transaction.

***Disclosure of Personal Benefits or Other Interests of Controlling Shareholders and Approval of Certain Transactions***



Pursuant to the Israel Companies Law, the disclosure requirements regarding personal benefits or other interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In this context, a controlling shareholder includes a shareholder who holds 25% or more of our outstanding shares if no other shareholder holds more than 50% of our outstanding shares. For this purpose, the holdings of all shareholders who have a personal benefit or other interest in the same transaction will be aggregated. The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (a) extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal benefit or other interest, (b) our engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to us, (c) the terms of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (d) our employment of a controlling shareholder or his or her relative, other than as an office holder. In addition to shareholder approval by a simple majority, the transaction must be approved by a Special Majority.

To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years, unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable under the circumstances.

Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require the approval of the compensation committee, board of directors and shareholders, in that order, by a Special Majority, and the terms must be consistent with our Compensation Policy.

Pursuant to regulations promulgated under the Israel Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, that would otherwise require approval of our shareholders may be exempt from shareholder approval upon certain determinations of the audit committee and board of directors. Under these regulations, we must publish these determinations, and a shareholder holding at least 1% of our outstanding shares may, within 14 days of after publication, demand shareholder approval despite such determinations.

### **Board Leadership Structure**

The Board has no policy regarding the need to separate or combine the offices of Chairman of the Board and Chief Executive Officer and remains free to make this determination from time to time in a manner that the Board deems most appropriate for our Company. Currently, we have separated the positions of CEO and Chairman of the Board in recognition of the differences between the two roles. The CEO is responsible for the day-to-day leadership and performance of the Company, while the Chairman of the Board (in collaboration with other members of the Board) sets the strategic direction of the Company, provides guidance to the management, sets the agenda for the Board meetings (in collaboration with the other members of the Board) and presides over meetings of the Board. We believe that separating these positions allows the Chairman of the Board to lead the board in its fundamental role of providing direction and guidance to management, while allowing our CEO to focus on our day-to-day operations. In addition, we believe that the current separation provides a more effective monitoring and objective evaluation of the performance of the CEO. The Board believes it is important that the Company retain organizational flexibility to determine whether the roles of CEO and Chairman of the Board should be separated or combined.

### **Risk Management**

The Board is actively involved in the oversight and management of risks that could affect the Company. This oversight and management is conducted primarily through committees of the Board, as disclosed in the descriptions of each of the committees above and in the charters of each of the committees, but the full Board has retained responsibility for general oversight of risks. The Board regularly receives reports from members of senior

management on areas of material risk to the Company, including operational, financial, regulatory and legal. The audit committee oversees management of financial risks (including liquidity and credit), approves all transactions with related persons and is primarily responsible for oversight of the Company's financial reporting process and internal control over financial reporting. The compensation committee is responsible for overseeing the management of risks relating to the Company's executive compensation plans and arrangements. The nominating and corporate governance committee oversees the Company's corporate governance programs, including the administration of the Code of Business Conduct and Ethics. The Board discharges its oversight responsibility through full reports by each committee chair regarding the relevant committee's actions, as well as through regular reports directly from officers responsible for oversight of particular risks within the Company.

### **Meetings Attended by Directors**

During the fiscal year ended December 31, 2017, the Board held a total of thirteen meetings, and each of our incumbent directors, except for Messrs. Wehrly and Ichiki and Ms. DiSanzo, attended at least 75% of the aggregate of the total number of meetings of the Board and the total number of meetings held by the committees of the Board on which he or she served during the period in which he or she served. Messrs. Wehrly and Ichiki and Ms. DiSanzo were unable to attend the meetings they missed due to work conflicts. The Board regularly holds executive sessions in which only its independent directors meet, without management present. Although we do not maintain a formal policy regarding director attendance at the annual general meeting of shareholders, in 2017 two of our directors, Jeff Dykan and Larry Jasinski, attended the annual general meeting of shareholders.

### **Code of Conduct and Ethics**

We adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which fulfills applicable guidelines issued by the SEC. The full text of the Code of Business Conduct and Ethics is posted at <http://ir.rewalk.com>. Information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Statement and is not incorporated by reference herein. We will also provide a hard copy of our Code of Business Conduct and Ethics free of charge upon written request to ReWalk Robotics, Ltd., 3 Hatnufa Street, Floor 6, Yokneam Ilit, 2026903, Israel. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment or waiver on our website within four business days to the extent required by the rules and regulations of the SEC. We granted no waivers under our Code of Business Conduct and Ethics in 2017.

### **AUDIT COMMITTEE REPORT**

On behalf of the Board of Directors of ReWalk Robotics Ltd. (the “Company”), the audit committee oversees the operation of the Company’s system of internal controls in respect of the integrity of its financial statements and reports, compliance with laws, regulations and corporate policies, and the qualifications, performance and independence of its independent registered public accounting firm. Management has the primary responsibility for the Company’s financial statements and financial reporting process, and the Company’s independent registered public accounting firm is responsible for auditing those financial statements.

Consistent with its oversight responsibility, the audit committee has reviewed and discussed with management and its independent registered public accounting firm the audited consolidated financial statements of the Company for the year ended December 31, 2017 and the results of management's assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2017.

The audit committee has also discussed with the Company's independent registered public accounting firm the matters required to be discussed under applicable Public Company Accounting Oversight Board ("PCAOB") rules, including the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of the disclosures in the financial statements. The Company's independent registered public accounting firm also provided to the audit committee the written disclosures and letter regarding their independence required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm's communications with the audit committee concerning independence. The audit committee also discussed with the independent registered public accounting firm their independence from the Company and its management, and considered whether the non-audit services provided by the independent registered public accounting firm to the Company are compatible with maintaining the firm's independence.

The audit committee discussed with the Company's independent registered public accounting firm the overall scope and plans for its audit. The audit committee met with the independent registered public accounting firm to discuss the results of its examinations and the overall quality of the Company's financial reporting.

Based on the audit committee's review of the audited financial statements and the review and discussions described in the foregoing paragraph, the audit committee recommended to the Board that the audited financial statements for the fiscal year ended December 31, 2017, be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, for filing with the Securities and Exchange Commission. The audit committee has selected Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018, and has asked the shareholders to ratify the selection.

The Audit Committee

Dr. John William Poduska  
Peter Wehrly  
Wayne Weisman

*The foregoing report of the audit committee of the Board of Directors shall not be deemed to be soliciting material or be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act, except to the extent we specifically incorporate this information by reference, and shall not otherwise be deemed to be filed with the SEC under the Securities Act or the Exchange Act.*

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

As of March 1, 2018, there were 30,006,575 ordinary shares outstanding, excluding ordinary shares issuable in connection with the exercise of outstanding warrants or outstanding options or upon the vesting of RSUs. The voting rights of all shareholders are the same. Each ordinary share is entitled to one vote upon each matter to be presented at the Meeting.

The following table sets forth certain information as of March 1, 2018, concerning the number of ordinary shares beneficially owned, directly or indirectly, by:

- (1) each person, or group of affiliated persons, known to us to beneficially own more than 5% of our outstanding ordinary shares;
- (2) each of our directors and director nominees;
- (3) each of our Named Executive Officers (as defined under “Summary Compensation Table” below); and
- (4) all of our directors and executive officers serving as of March 1, 2018, as a group.

Beneficial ownership is determined in accordance with the rules of the SEC based on voting and investment power with respect to such shares. Shares subject to options or warrants that are currently exercisable or exercisable within 60 days of March 1, 2018, and shares subject to RSUs that were vested as of or will vest within 60 days of March 1, 2018, are deemed to be outstanding and to be beneficially owned by the person holding such options, RSUs or warrants for the purpose of computing the percentage ownership of such person. However, such shares are not deemed to be outstanding and to be beneficially owned for the purpose of computing the percentage ownership of any other person. All information with respect to the beneficial ownership of any principal shareholder has been furnished by such shareholder or is based on our filings with the SEC and, unless otherwise indicated below, we believe that persons named in the table have sole voting and sole investment power with respect to all the ordinary shares shown as beneficially owned, subject to community property laws, where applicable. The ordinary shares beneficially owned by our directors and officers may include shares owned by their respective family members, as to which such directors and officers disclaim beneficial ownership. Unless otherwise noted below, each shareholder’s address is c/o ReWalk Robotics Ltd., 3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel.

<b>Name</b>	<b>Number of Shares</b>	<b>Percentage of Shares</b>
Principal Shareholders:		
Kreos Capital V (Expert Fund) Limited <sup>(1)</sup>	2,690,672	9%

Edgar Filing: ReWalk Robotics Ltd. - Form PRE 14A

Entities affiliated with SCP Vitalife Partners <sup>(2)</sup>	1,529,962	5.1%
Yaskawa Electric Corporation <sup>(3)</sup>	1,561,968	5.2%
Named Executive Officers and Directors:		
Larry Jasinski <sup>(4)</sup>	411,554	1.4%
Kevin Hershberger <sup>(5)(6)</sup>	169,478	*
Jeff Dykan <sup>(2)(7)</sup>	1,546,404	5.2%
Deborah DiSanzo <sup>(8)</sup>	20,895	*
Wayne B. Weisman <sup>(2)(7)</sup>	1,546,404	5.2%
Aryeh (Arik) Dan <sup>(7)</sup>	16,442	*
Yasushi Ichiki <sup>(7)</sup>	16,442	*
Dr. John William Poduska <sup>(9)</sup>	28,988	*
Peter Wehrly <sup>(10)</sup>	19,854	*
Ofir Koren <sup>(11)</sup>	33,100	*
All directors and executive officers as a group (10 persons) <sup>(12)</sup>	2,112,946	6.9%

\* Ownership of less than 1%.

- The number of shares beneficially owned consists of (i) up to 167,012 ordinary shares issuable upon the exercise of currently exercisable warrants to purchase ordinary shares at an exercise price of \$9.64 per share (subject to customary anti-dilution adjustments), which were granted on December 31, 2015 and December 28, 2016 to Kreos Capital V (Expert Fund) Limited (“Kreos V”) in connection with the loan agreement, dated December 30, 2015, as amended on June 9, 2017 (the “Kreos V Loan Agreement”), between us and Kreos, pursuant to which
- (1) Kreos extended a line of credit to us in the amount of \$20.0 million; and (ii) up to 2,523,660 ordinary shares issuable upon the conversion of the \$3.0 million convertible note (the “Kreos V Convertible Note”) issued to Kreos V on June 9, 2017 at a conversion price of \$1.268 per share (subject to customary anti-dilution adjustments), which is currently convertible by Kreos V at its option. For more information, see “Certain Relationships and Related Transactions and Director Independence—Related Party Transactions—The Kreos Transactions.” The address of Kreos V, which is organized under the laws of Jersey, is 47 Esplanade, St Helier, Jersey. Based on filings made with the SEC, consists of 1,017,674 ordinary shares and warrants to purchase 22,374 ordinary shares beneficially owned by SCP Vitalife Partners II, L.P. (“SCP Vitalife Partners II”), a limited partnership organized in the Cayman Islands, 339,900 ordinary shares and warrants to purchase 7,488 ordinary shares beneficially owned by SCP Vitalife Partners (Israel) II, L.P. (“SCP Vitalife Partners Israel II”), a limited partnership organized in Israel, 62,006 ordinary shares beneficially owned by Vitalife Partners (Overseas) L.P. (“Vitalife Partners Overseas”), 20,506 ordinary shares beneficially owned by Vitalife Partners (Israel) L.P. (“Vitalife Partners Israel”), 20,733 ordinary shares beneficially owned by Vitalife Partners (D.C.M) L.P. (“Vitalife Partners DCM”) and 39,281 ordinary shares currently held by the Israel Innovation Authority (formerly known as the Office of the Chief Scientist of the State of Israel) (the “IIA”), that Vitalife Partners Overseas, Vitalife Partners Israel and Vitalife Partners DCM have the right to acquire from IIA. SCP Vitalife II Associates, L.P. (“SCP Vitalife Associates”), a limited partnership organized in the Cayman Islands, is the general partner of the SCP Vitalife Partners II and SCP Vitalife Partners Israel II, and SCP Vitalife II GP, Ltd. (“SCP Vitalife GP”), organized in the Cayman Islands, is the general partner of SCP Vitalife Associates. As such, SCP Vitalife GP may be deemed to beneficially own the 1,387,436 ordinary shares beneficially owned by SCP Vitalife Partners II and SCP Vitalife Israel Partners II. Winston J. Churchill, Jeff Dykan, Abraham Ludomirski, and Wayne B. Weisman are the directors of SCP Vitalife GP and, as such, share voting and dispositive power over the shares held by the foregoing entities. As such, they may be deemed to beneficially own 1,529,962 ordinary shares, consisting of the 1,387,436 ordinary shares beneficially owned by SCP Vitalife GP, as well as the ordinary shares beneficially owned by each of Vitalife Partners Overseas, Vitalife Partners Israel and Vitalife Partners DCM and held by IIA. The principal business address of SCP Vitalife Partners II, SCP Vitalife Associates, SCP Vitalife GP, and Messrs. Churchill and Weisman is c/o SCP Vitalife Partners II, L.P., 1200 Liberty Ridge Drive, Suite 300, Wayne, Pennsylvania 19087. The principal business address of SCP Vitalife Partners Israel II, Vitalife Partners Israel, Vitalife Partners Overseas, Vitalife Partners DCM, Mr. Dykan and Dr. Ludomirski is c/o SCP Vitalife Partners (Israel) II, L.P., 32B Habarzel Street, Ramat Hachayal, Tel Aviv 69710, Israel. Based on filings made with the SEC, consists of 1,561,968 ordinary shares beneficially owned by Yaskawa Electric Corporation. Yaskawa Electric Corporation is a widely-held Japanese corporation the securities of which
  - (3) are listed on the Tokyo Stock Exchange. Its address is 2-1 Kurosakishiroishi, Yahatanishi-ku, Kitakyushu 806-0004, Japan.
  - (4) Consists of 21,031 ordinary shares, exercisable options to purchase 389,250 ordinary shares and 1,273 ordinary shares underlying vested RSUs.
  - (5) Mr. Hershberger resigned as Chief Financial Officer, effective February 22, 2018, and is included solely due to his status as a “named executive officer” (as defined in Item 402 of Regulation S-K) for SEC disclosure purposes. Consists of 2,870 ordinary shares, exercisable options to purchase 25,875 ordinary shares and 3,272 ordinary shares underlying vested RSUs.
  - (6) Consistent with the previously-disclosed terms of Mr. Hershberger’s grants, the 2014 Plan and the Equity Exchange Program, on February 14, 2018, the compensation committee accelerated options to purchase 77,625 ordinary shares and 59,836 ordinary shares underlying vested RSUs.



- (7) Consists of 6,002 ordinary shares underlying vested RSUs and exercisable options to purchase 10,440 ordinary shares.
- (8) Consists of exercisable options to purchase 20,895 ordinary shares.
- (9) Consists of 6,002 ordinary shares underlying vested RSUs and exercisable options to purchase 22,986 ordinary shares underlying vested RSUs.
- (10) Consists of exercisable options to purchase 19,854 ordinary shares.

- (11) Consists of 2,873 ordinary shares underlying vested RSUs and exercisable options to purchase 30,227 ordinary shares.

Excludes ordinary shares beneficially owned by Mr. Hershberger, one of our “named executive officers” (as defined in Item 402 of Regulation S-K) solely for SEC disclosure purposes who was no longer an executive officer as of March 1, 2018, and includes ordinary shares owned by all executive officers as of such date, namely, Mr.

- (12) Consists of (i) 1,554,964 ordinary shares directly or beneficially owned by the Company’s directors and executive officers; (ii) 526,847 ordinary shares constituting the cumulative aggregate number of options granted to the executive officers and directors that are currently exercisable or exercisable within 60 days of March 1, 2018; (iii) 1,273 ordinary shares constituting the cumulative aggregate number of RSUs granted to the executive officers and directors that were vested as of or will vest within 60 days of March 1, 2018; and (iv) warrants to purchase 29,862 ordinary shares beneficially owned by certain of the Company’s directors.

**DIRECTOR COMPENSATION**

The following table provides certain information concerning the compensation for services rendered in all capacities by each non-employee director serving on our Board during the year ended December 31, 2017, other than Mr. Larry Jasinski, our CEO, who did not receive additional compensation for his services as director and whose compensation is set forth in the Summary Compensation Table found elsewhere in this Proxy Statement.

<b>Name</b>	<b>Fees Earned in Cash(\$)</b>	<b>Option Awards\$(1)</b>	<b>Total (\$)</b>
Jeff Dykan	-	4,570	4,570
Deborah DiSanzo	30,334(2)	4,570	34,904
Aryeh (Arik) Dan	-	4,570	4,570
Yasushi Ichiki	-	4,570	4,570
Glenn Muir(3)	43,358(4)	4,570	47,928
Dr. John William Poduska	44,649(5)	4,570	49,219
Peter Wehrly	31,052(6)	4,570	35,622
Wayne B. Weisman(7)	-	4,570	4,570

Amounts represent the aggregate grant date fair value of an award of options to purchase 4,176 ordinary shares issued to each of the directors under the 2014 Equity Incentive Plan (the “2014 Plan”), computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC Topic 718”). All (1) options become vested and exercisable in four equal quarterly installments starting three months following the grant date. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

(2) Represents \$23,668 earned by Ms. DiSanzo as an annual retainer for serving as a member of the Board of Directors and \$6,666 for attending meetings of the Board of Directors.

(3) Mr. Muir resigned from the Board and all committees of the Board effective December 29, 2017.

Represents \$23,668 earned by Mr. Muir as an annual retainer for serving as an external director on the Board of Directors, \$8,630 for attending meetings of the Board of Directors, \$4,314 for serving as the chairman of the audit (4) committee, \$5,033 for serving as a member of the compensation committee and \$1,713 for serving as a member of the Company’s finance committee established for its securities offerings. For more information on external directors, see “Opt-Out of Certain Israel Companies Law Requirements” above.

Represents \$23,668 earned by Dr. Poduska as an annual retainer for serving as an external director on the Board of Directors, \$9,177 for attending meetings of the Board of Directors, \$4,694 for serving as a member of the audit (5) committee, \$5,397 for serving as the chairman of the compensation committee and \$1,713 for serving as a member of the Company’s finance committee established for its securities offerings. For more information on external directors, see “Opt-Out of Certain Israel Companies Law Requirements” above.

Represents \$23,668 earned by Mr. Wehrly as a portion of the annual retainer for serving as a member of the Board (6) of Directors, \$5,134 for attending meetings of the Board of Directors and \$2,250 for serving as a member of the audit committee.

(7)

Mr. Weisman was appointed a member of the audit committee on December 29, 2017 following Mr. Muir's resignation. Mr. Weisman did not receive any fees for serving on the audit committee during the year ended December 31, 2017.

The aggregate number of ordinary shares subject to outstanding options and RSU awards for each of our non-employee directors as of December 31, 2017 is shown below. Information regarding Mr. Jasinski's outstanding equity awards as of December 31, 2017 is set forth in the Outstanding Equity Awards Table found elsewhere in this Proxy Statement.

<b>Name</b>	<b>Number of Shares</b>
Jeff Dykan	12,528(1)
Deborah DiSanzo	25,074
Wayne B. Weisman	12,528(2)
Aryeh (Arik) Dan	12,528
Yasushi Ichiki	12,528
Glenn Muir	25,074
Dr. John William Poduska	25,074
Peter Wehrly	20,898

(1) See "Security Ownership of Certain Beneficial Owners and Management" above for further information on Mr. Dykan's holdings in our ordinary shares.

(2) See "Security Ownership of Certain Beneficial Owners and Management" above for further information on Mr. Weisman's holdings in our ordinary shares.

Cash compensation for our independent, non-employee directors' services is governed by regulations promulgated under the Israel Companies Law (the "Compensation Regulations") and by previous decisions of our compensation committee, Board and shareholders. In accordance with the Compensation Regulations, we pay our independent, non-employee directors the maximum annual cash fee and the maximum per meeting cash attendance fee set forth in the Compensation Regulations for experts. Additionally, the amounts payable by a company to external directors under the Compensation Regulations are based on the amount of the company's shareholders' equity as of the end of the previous year. Accordingly, in 2017 we paid our independent, non-employee directors, Peter Wehrly and Deborah DiSanzo, and our external directors, Glenn Muir and Dr. John William Poduska, NIS 83,480 (approximately \$24,197 based on current exchange rates) per year and NIS 4,390 (approximately \$1,273 based on current exchange rates) per meeting attended in person, and 60% of such amount (approximately \$764 based on current exchange rates) for attending any meeting by telephone and 50% of such amount (approximately \$637 based on current exchange rates) for any action by written consent. As described above under "Opt-Out of Certain Israel Companies Law Requirements," on February 8, 2018, we opted out of certain Israel Companies Law Requirements, including the requirement for our Board to include at least two directors each of whom satisfies the requirements of an "external director" under the Israel Companies Law.

Additionally, each independent, non-employee director who is appointed currently receives upon his or her appointment options to purchase 12,546 ordinary shares and annual awards of options to purchase 4,176 ordinary

shares, all of which vest ratably in four equal quarterly installments starting three months from the date of grant. As discussed below under Proposal Two, we are proposing to revise our non-employee directors' equity compensation. In addition, each director is reimbursed for out-of-pocket expenses in connection with attending meetings of the Board or committees. Directors are also indemnified and insured by us for actions associated with being a director to the extent permitted under Israeli law. For further discussion, see "Certain Relationships and Related Transactions—Agreements with Directors and Officers." Further, none of our non-employee directors receive any benefits upon termination of their directorship positions. Our non-employee directors are eligible to receive awards under certain of our equity compensation plans described below under "Executive Compensation—Equity Compensation Plans." The compensation committee reviews director compensation annually and makes recommendations to the Board with respect to compensation and benefits provided to the members of the Board.

**EXECUTIVE COMPENSATION**

As an emerging growth company, we have opted to comply with the executive compensation rules otherwise applicable to “smaller reporting companies,” as such term is defined in Rule 12b-2 under the Exchange Act.

**Summary Compensation Table**

The table below provides certain information concerning the compensation for services rendered to us during the years ended December 31, 2016 and December 31, 2017 by (1) all individuals who served as our Chief Executive Officer during any part of the year ended December 31, 2017 and (2) our two most highly compensated executive officers (other than our Chief Executive Officer) who were serving as executive officers as of December 31, 2017 (together, our “Named Executive Officers”).

<b>Name and Principal Position</b>	<b>Year</b>	<b>Salary (\$)</b>	<b>Bonus (\$)(1)</b>	<b>Stock Awards (\$)(2)</b>	<b>Option Awards (\$)(2)</b>	<b>All Other Compensation (\$)(3)</b>	<b>Total (\$)</b>
Larry Jasinski, Chief Executive Officer and Director(4)	2017	377,500	157,975	98,420(5)	136,750(6)	-	770,645
	2016	370,000	123,488	174,000(19)	445,418(7)	-	1,112,906
Kevin Hershberger, former Chief Financial Officer (8)	2017	266,825	74,581	79,729(9)	111,263(10)	-	532,398
	2016	260,000	77,403	145,376(20)	400,176(11)	-	882,955
Ofir Koren, Vice President, Research & Development and Regulatory(12)	2017	170,645	29,811	23,349(13)	40,313(14)	67,590(17)	331,708
	2016	154,185	20,189	31,624(15)	86,753(16)	57,904(18)	350,655

(1) Represents one-time discretionary cash bonuses to each of the Named Executive Officers.

Amounts represent the aggregate grant date fair value of such awards computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

(3)

Amounts reported in this column include benefits and perquisites, including those mandated by Israeli law. Such benefits and perquisites include payments, contributions and/or allocations for social benefits and car expenses.

(4) Mr. Jasinski does not receive any additional compensation for his services as a director. See "Director Compensation" above.

Consists of 25,000 RSUs that were granted under the 2014 Plan to Mr. Jasinski on June 27, 2017, which vest ratably in four equal annual installments starting on the first anniversary of the grant date, and 78,285 RSUs that (5) were granted to Mr. Jasinski in connection with the cancellation of certain underwater stock options as part of the Equity Exchange Program on October 5, 2017, which vest ratably in three equal annual installments starting on the first anniversary of the grant date. For more information, see "—Equity Exchange Program" below.

Consists of options to purchase 125,000 ordinary shares that were granted to Mr. Jasinski on June 27, 2017, with 25% of the options to vest on the first anniversary of the grant date and 6.25% of the options to vest and become exercisable on a quarterly basis thereafter. The options will also vest as follows: (A) 100% of the then-unvested options shall automatically vest upon the occurrence of an "Exit Event" (as defined below under "Proposal Four - Background") and the termination of Mr. Jasinski's employment within 12 months following such Exit Event, other (6) than a termination for cause (as defined in Mr. Jasinski's employment agreement with the Company, as described below); or (B) upon a termination of Mr. Jasinski's employment by the ReWalk Robotics, Inc., our wholly-owned U.S. subsidiary (the "Subsidiary") without "cause" or by Mr. Jasinski for "Good Reason" (both as defined in Mr. Jasinski's employment agreement) prior to an Exit Event, any unvested options that would have vested during the six months following the effective date of such termination had Mr. Jasinski remained employed by the Subsidiary during such period will automatically vest.

Consists of options to purchase 100,000 ordinary shares that were granted under the 2014 Plan to Mr. Jasinski on (7) May 24, 2016. All such options were replaced with RSUs as part of the Equity Exchange Program. For more information, see "—Equity Exchange Program" below.

(8) Mr. Hershberger resigned as Chief Financial Officer, effective February 22, 2018.

Consists of 19,250 RSUs that were granted under the 2014 Plan to Mr. Hershberger on April 18, 2017, which vest ratably in four equal annual installments starting on the first anniversary of the grant date, and 62,006 RSUs that (9) were granted to Mr. Hershberger in connection with the cancellation of certain underwater stock options as part of the Equity Exchange Program on October 5, 2017, which vest ratably in three equal annual installments starting on the first anniversary of the grant date. For more information, see "—Equity Exchange Program" below.

Consists of options to purchase 103,500 ordinary shares that were granted under the 2014 Plan to Mr. (10) Hershberger on April 18, 2017, with 25% of the options to vest on the first anniversary of the grant date and 6.25% of the options to vest and become exercisable on a quarterly basis thereafter.

Consists of options to purchase 82,800 ordinary shares that were granted under the 2014 Plan to Mr. Hershberger on May 18, 2016, with 25% of the options to vest on the first anniversary of the grant date and 6.25% of the (11) options to vest and become exercisable on a quarterly basis thereafter. All such options were replaced with RSUs as part of the Equity Exchange Program. For more information, see "—Equity Exchange Program" below.

The amounts set forth for Mr. Koren in the columns "Salary," "Bonus," and "All Other Compensation" represent (12) payments, contributions and/or allocations that were made in NIS, and have been translated to US dollars according to the average exchange rate on the applicable period.

Consists of 7,500 RSUs that were granted under the 2014 Plan to Mr. Koren on April 18, 2017, which vest ratably in four equal annual installments starting on the first anniversary of the grant date, and 13,401 RSUs that (13) were granted to Mr. Koren in connection with the cancellation of certain underwater stock options as part of the Equity Exchange Program on October 5, 2017, which vest ratably in three equal annual installments starting on the first anniversary of the grant date. For more information, see "—Equity Exchange Program" below.

Consists of options to purchase 37,500 ordinary shares that were granted to Mr. Koren on April 18, 2017, with (14) 25% of the options to vest on the first anniversary of the grant date and 6.25% of the options to vest and become exercisable on a quarterly basis thereafter.





- (15) Consists of 3,350 RSUs that were granted under the 2014 Plan to Mr. Koren on May 18, 2016, which vest ratably in four equal annual installments starting on the first anniversary of the grant date.
- (16) Consists of options to purchase 17,950 ordinary shares that were granted under the 2014 Plan to Mr. Koren on May 18, 2016. All such options were replaced with RSUs as part of the Equity Exchange Program. For more information, see “—Equity Exchange Program” below.
- (17) Consists of \$48,836 for payments, contributions and/or allocations for social benefits and the aggregate incremental cost to the Company of \$18,754 with respect to Mr. Koren’s personal use of a Company-leased car.
- (18) Consists of \$42,748 for payments, contributions and/or allocations for social benefits and the aggregate incremental cost to the Company of \$15,156 with respect to Mr. Koren’s personal use of a Company-leased car.
- (19) Consists of 20,000 RSUs that were granted under the 2014 Plan to Mr. Jasinski on May 24, 2016, of which RSUs vest with respect to 25% of the original number of ordinary shares subject thereto on the first anniversary of the grant date and 6.25% of the RSUs to vest on a quarterly basis thereafter.
- (20) Consists of 15,400 RSUs that were granted under the 2014 Plan to Mr. Hershberger on May 18, 2016, which vest ratably in four equal annual installments starting on the first anniversary of the grant date.

### **Equity Exchange Program**

On September 6, 2017, we commenced a one-time equity award exchange program (the “Equity Exchange Program”), offering to certain eligible employees, executive officers and consultants the opportunity to cancel certain outstanding “underwater” stock options issued under the 2014 Plan, in exchange for the grant under such plan of a lesser number of RSUs. The Company’s non-employee directors and retirees were not eligible to participate in the Equity Exchange Program. The Company conducted the Equity Exchange Program as a “value-for-value” exchange, pursuant to which the Company issued new RSUs with a value approximately equal to the value of the options that are surrendered, in accordance with the terms approved by the Company’s shareholders at the 2017 Annual Meeting of Shareholders. The primary purpose of the Equity Exchange Program was to restore the intended retention and incentive value of certain employee and consultant equity awards. Participation in the Equity Exchange Program was voluntary. The Company used the 52-week high closing price of its ordinary shares (as measured at the commencement of the Equity Exchange Program) as a threshold for options eligible to be exchanged.

Following the expiration of the Equity Exchange Program, on October 5, 2017, the Company granted to these holders an aggregate of 251,872 new RSUs. 180,167 of these new RSUs were granted to the Company’s executive officers and “named executive officers” named in the definitive proxy statement on Schedule 14A relating to the 2017 Annual Meeting of Shareholders. Mr. Jasinski received 78,285 new RSUs, Mr. Hershberger received 62,006 new RSUs and Mr. Koren received 13,401 new RSUs. Unless the Company’s compensation committee accelerates their vesting, the new RSUs vest over a three-year period, with one-third vesting on the first anniversary of the date of grant and one-third vesting on each of the next two successive anniversaries. Additionally, the forfeiture terms of the new RSUs are substantially the same as those that apply generally to previously-granted RSUs granted under the 2014 Plan. The stock options exchanged pursuant to the Exchange Program were canceled and the ordinary shares underlying such options became available for issuance under the 2014 Plan.

The modification was analyzed under ASC No. 718 to determine if the new vesting conditions remain probable, as the original. Since the modification also increased the fair value of the Equity Exchange Program, the Company decided to implement one of the two acceptable methods and recognize the incremental compensation amounted as \$159,000 over the new service period. The unrecognized compensation cost remaining from the original grant will be recognized over the remainder of the original requisite service period.

## Employment Agreements of Named Executive Officers

Each of Larry Jasinski, our Chief Executive Officer, and Kevin Hershberger, our former Chief Financial Officer, previously entered into employment agreements with our Subsidiary, and Ofir Koren, our Vice President, Research & Development and Regulatory, previously entered into an employment agreement with us. These employment agreements set forth their respective terms of employment, which terms are generally applicable to all of our executives, covering matters such as vacation, health, and other benefits. The following are descriptions of the material terms of our Named Executive Officers' employment agreements.

### *Larry Jasinski*

On January 17, 2011, we entered into an employment agreement with Mr. Jasinski, pursuant to which he has served as the Chief Executive Officer of the Company since February 12, 2012. The employment agreement provides for an annual base salary of \$325,000, subject to annual review by, and increases in the discretion of, the Company, and an annual performance bonus of up to 35% of annual base salary. In the event that Mr. Jasinski's employment is terminated by the Company without cause (as defined in the employment agreement), or if Mr. Jasinski terminates his employment for "Good Reason" (as defined in the employment agreement), he will be entitled to certain severance payments and benefits, including: (i) a lump sum payment equal to 90 days of his base salary, (ii) an annual performance bonus (calculated based on the assumption that to the extent performance objectives were achieved in the six-month period preceding his termination, they will also be achieved in the six months following termination), (iii) reimbursement for any COBRA or other medical, dental and vision premiums for twelve months following his termination and (iv) continued participation for a period of twelve months in any employee and executive benefit programs in effect as of his termination and reimbursement for the premium or other fees associated with continuation in any insurance program available to the Company's employees as a non-employee or in a comparable program if participation as a non-employee would be barred. The employment agreement further provides that if Mr. Jasinski's employment is terminated without cause or by Mr. Jasinski for Good Reason, any unvested portion of the options which would have vested during the six months following such termination had Mr. Jasinski remained employed by the Company, will automatically vest. If Mr. Jasinski terminates his employment without Good Reason, he will be entitled to receive a pro-rated amount of his annual performance bonus as determined in good faith by the Board. Mr. Jasinski is not entitled to any severance if he is terminated by the Company for cause.

The employment agreement is governed by the laws of the State of Delaware and contains non-solicitation and non-competition covenants (each of which remains in effect during the term of employment and for 12 months following termination of employment) and trade secrets and inventions clauses.

### *Kevin Hershberger*

On December 17, 2014, we entered into an employment agreement with Mr. Kevin Hershberger, pursuant to which he served as the Chief Financial Officer of the Company from January 1, 2015 until his resignation effective February 22, 2018. Following the effective date of his resignation, Mr. Hershberger is still engaged by the Company and providing services as a non-executive employee until March 31, 2018. The employment agreement was for a one-year term which ended on January 1, 2016 and was automatically renewed for additional one-year terms in each of 2016 and 2017 and for 2018 through March 31, 2018, when Mr. Hershberger will cease being engaged by the Company. Pursuant to his employment agreement, Mr. Hershberger is entitled to an annual base salary of \$250,000, subject to increases as determined from time to time by the compensation committee, and an annual performance bonus up to 35% of annual base salary. Performance that exceeded the agreed upon objectives allowed for payment beyond the 35% target. Pursuant to the terms of Mr. Hershberger's employment agreement, effective March 31, 2018, the termination date of Mr. Hershberger's services, Mr. Hershberger will be eligible to receive severance pay equal to six months of his salary and cash bonus, as determined by the compensation committee, along with the replacement cost of his benefits. He will also be entitled to receive a cash bonus for the three-month period he served in 2018, to be determined by the compensation committee. Consistent with the previously-disclosed terms of Mr. Hershberger's grants under the 2014 Plan, on February 14, 2018, in connection with the termination of Mr. Hershberger's service effective March 31, 2018, the compensation committee accelerated all of Mr. Hershberger outstanding equity awards. Mr. Hershberger will be able to exercise his outstanding options for a period of 12 months following the termination of his employment.

The employment agreement is governed by the laws of the Commonwealth of Massachusetts and contains non-solicitation and non-competition covenants (each of which remains in effect for 12 months following termination of employment) and trade secrets and inventions clauses.

*Ofir Koren*

On January 15, 2013, we entered into an employment agreement with Mr. Ofir Koren. Pursuant to the employment agreement, Mr. Koren was appointed as our Vice President, Research and Development. The employment agreement, as amended, is not for any specific term and may be terminated by either party upon three months' prior written notice (the "Notice Period").

Pursuant to the employment agreement, Mr. Koren was entitled to an annual base salary of NIS 540,000 (approximately \$156,520 based on current exchange rates), subject to increases as may be determined from time to time by the compensation committee. The amount of Mr. Koren's annual base salary was subsequently amended by the Company's compensation committee to be equal to NIS 619,560 (approximately \$179,580 based on current exchange rates). Pursuant to the employment agreement, Mr. Koren was also entitled to an annual performance bonus equal to up to 20% of his annual base salary. The amount of the annual performance bonus has been subsequently amended by the Company's compensation committee to be equal to up to 25% of Mr. Koren's annual base salary. Mr. Koren will be entitled to his bonus post-termination, to the extent that he is terminated other than for cause (as defined in his employment agreement) after achieving his performance target but before receiving his bonus. Mr. Koren is also entitled to use of a Company-provided car and related maintenance expenses (returnable to the Company upon termination of employment). In the event that Mr. Koren's employment is terminated by the Company (except if terminated by the Company for cause) or by Mr. Koren, Mr. Koren may be entitled to receive severance pay in such amounts as determined under and accordance with Section 14 of the Israel Severance Pay Law 5723-1963.

Mr. Koren's employment agreement is governed by the laws of the State of Israel and contains non-solicitation and non-competition covenants (each of which remains in effect during the term of employment and for a period of 12 months following termination of employment) and trade secrets and inventions clauses. The Company may also terminate Mr. Koren's employment immediately without providing prior notice (i) for cause (as defined in his employment agreement) or (ii) if the Company pays Mr. Koren a lump sum equal to the salary to which he would have been entitled during the Notice Period.

**2018 Non-Equity Incentive Plan**

All employees, including our named executive officers, are eligible to participate in a non-equity incentive plan for fiscal year 2018, pursuant to which employees are eligible to receive a bonus with respect to their performance in such year. Each employee's target is equal to a specified percentage of his or her base salary, and the actual bonus will be paid based on the achievement of certain business and personal performance objectives for the 2018 fiscal year. Not all goals will need to be met to receive a portion of the bonus. The business performance objective under the non-equity incentive plan for 2018 is based on achieving specified financial goals or milestones as set forth in the Compensation Policy as approved by the Company's shareholders (allocated 25% for revenue targets, 25% for

reimbursement targets, 15% for product development targets and 15% for cash management targets). A personal performance objective, which is subjective in nature, makes up the remaining 20%.

If the target is met in all categories of the business performance objective, 100% of the employee's bonus will be paid. If certain lower targets are met with respect to revenue, reimbursement and product development, between 50% and 75% of the employee's bonus will be paid. If targets are exceeded in all categories of the business performance objective, 150% of the bonus will be paid.

## EQUITY COMPENSATION PLANS

### *2014 Equity Incentive Plan*

On August 19, 2014, we adopted the 2014 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, cash-based awards, other stock-based awards and dividend equivalents to our company's and our affiliates' respective employees, non-employee directors and consultants. Pursuant to an "evergreen" provision, the reserved pool of shares under the 2014 Plan increases on January 1 of each calendar year during the term of the 2014 Plan by a number of shares equal to the lesser of: (i) 972,000, (ii) 4% of the total number of shares outstanding on December 31 of the immediately preceding calendar year, and (iii) an amount determined by our Board. The reserved pool of shares under the 2014 Plan also includes (i) the number of shares available for issuance under our 2012 Equity Incentive Plan, our 2012 Israeli Sub Plan and our 2006 Stock Option Plan (collectively, the "Prior Plans") as of the effective date of the 2014 Plan (in an amount not to exceed 128,106 shares) and (ii) shares underlying awards that are forfeited, cancelled or terminated, expire unexercised or are settled in cash in lieu of issuance, in each case, under the Prior Plans, in an amount not to exceed 1,115,640 ordinary shares. From and after the effective date of the 2014 Plan, no further grants or awards shall be made under the Prior Plans. Generally, shares that are forfeited, cancelled, terminated or expire unexercised or settled in cash in lieu of issuance of shares under the 2014 Plan shall be available for issuance under new awards. Generally, any shares tendered or withheld under the 2014 Plan to pay the exercise price, purchase price of an award, or any withholding taxes shall be available for issuance under new awards. Shares delivered pursuant to "substitute awards" (awards granted in assumption or substitution of awards granted by a company acquired by us) shall not reduce the shares available for issuance under the 2014 Plan. As of March 1, 2018, there were 1,219,557 ordinary shares subject to outstanding awards under the 2014 Plan, including options to purchase 642,822 ordinary shares and 576,735 ordinary shares underlying unvested RSUs, and 2,409,934 shares available for future grants.

The 2014 Plan is administered by the compensation committee which has authority in all matters related to the discharge of its responsibilities and the exercise of its authority under the plan. Awards under the 2014 Plan may be granted until ten years after the date on which the 2014 Plan was approved by our shareholders.

The terms of options granted under the 2014 Plan, including the exercise price, vesting provisions and the duration of an option, shall be determined by the compensation committee and set forth in an award agreement. Except as provided in the applicable award agreement, or in the discretion of the compensation committee, an option may be exercised only to the extent that it is then exercisable and shall terminate immediately upon a termination of service of the grantee.

Stock appreciation rights ("SARs") are awards entitling a grantee to receive a payment representing the difference between the base price per share of the right and the fair market value of a share on the date of exercise. SARs may be

granted in tandem with an option or independent and unrelated to an option. The terms of SARs granted under the 2014 Plan, including the base price per share, vesting provisions and the duration of an SAR, shall be determined by the compensation committee and set forth in an award agreement. Except as provided in the applicable award agreement, or in the discretion of the compensation committee, a SAR may be exercised only to the extent that it is then exercisable and shall terminate immediately upon a termination of service of the grantee. At the discretion of the compensation committee, SARs will be payable in cash, ordinary shares or equivalent value or some combination thereof.

Restricted stock awards are ordinary shares that are awarded to a grantee subject to the satisfaction of the terms and conditions established by the compensation committee in the award agreement. Until such time as the applicable restrictions lapse, restricted shares are subject to forfeiture and may not be sold, assigned, pledged or otherwise disposed of by the grantee who holds those shares.



RSUs are awards covering a number of hypothetical units with respect to shares that are granted subject to such vesting and transfer restrictions and conditions of payment as the compensation committee may determine in an award agreement. RSUs are payable in cash, ordinary shares of equivalent value or a combination thereof.

The 2014 Plan provides for the grant of cash-based award and other stock-based awards (which are equity-based or equity related award not otherwise described in the 2014 Plan). The terms of such cash-based awards or other stock-based awards shall be determined by the compensation committee and set forth in an award agreement.

The compensation committee may grant dividend equivalents based on the dividends declared on shares that are subject to any award. Dividend equivalents may be subject to any limitations and/or restrictions determined by the compensation committee and shall be converted to cash or additional shares by such formula and at such time, and shall be paid at such times, as may be determined by the compensation committee.

In the event of any dividend (excluding any ordinary dividend) or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, split-off, combination, repurchase or exchange of shares or similar event (including a change in control) that affects the ordinary shares, the compensation committee shall make any such adjustments in such manner as it may deem equitable, including, but not limited to, any or all of the following: (i) adjusting the number of shares available for grant under the 2014 Plan, (ii) adjusting the terms of outstanding awards, (iii) providing for a substitution or assumption of awards and (iv) cancelling awards in exchange for a payment in cash. In the event of a change of control, each outstanding award shall be treated as the compensation committee determines, including, without limitation, (i) that each award be honored or assumed, or equivalent rights substituted therefor, by the new employer or (ii) that all unvested awards will terminate upon the change in control. Notwithstanding the foregoing, in the event that it is determined that neither (i) or (ii) in the preceding sentence will apply, all awards will become fully vested.

#### *2014 U.S. Sub Plan*

The 2014 U.S. Sub Plan applies to grantees that are subject to U.S. federal income tax. The 2014 U.S. Sub Plan provides that options granted to the U.S. grantees will either be incentive stock options pursuant to Section 422 of the Internal Revenue Code or nonstatutory stock options. Options, other than certain incentive stock options described below, must have an exercise price not less than 100% of the fair market value of an underlying share on the date of grant. Incentive stock options that are not exercised within ten years from the grant date expire, provided that incentive stock options granted to a person holding more than 10% of our voting power will expire within five years from the date of the grant and must have an exercise price at least equal to 110% of the fair market value of an underlying share on the date of grant. The number of shares available under the 2014 Plan for grants of incentive stock options shall be the total number of shares available under the 2014 Plan subject to any limitations under the Internal Revenue Code and provided that shares delivered pursuant to “substitute awards” shall reduce the shares available for

issuance of incentive stock options under the 2014 Plan. It is the intention that no award shall be deferred compensation subject to Section 409A of the Internal Revenue Code unless and to the extent that the compensation committee specifically determines otherwise. If the compensation committee determines an award will be subject to Section 409A of the Internal Revenue Code such awards shall be intended to comply in all respects with Section 409A of the Code, and the 2014 Plan and the terms and conditions of such awards shall be interpreted and administered accordingly.

### *2012 Equity Incentive Plan*

On March 30, 2012, we adopted our 2012 Equity Incentive Plan, or the 2012 Plan, which was approved by our shareholders on the same date. The 2012 Plan provides for the grant of options, restricted shares, restricted share units, share appreciation rights, performance units, performance shares and other shares or cash awards to our company's and our affiliates' respective employees, directors and consultants. As of March 1, 2018, options to purchase 684,283 ordinary shares were outstanding under the 2012 Plan. The 2012 Plan was terminated on August 19, 2014, although option awards outstanding as of that date will continue in full force in accordance with the terms under which they were granted. In the event that any award shall for any reason expire or terminate without having been exercised or paid in full, the shares not acquired shall revert to the 2014 Plan and again become available for issuance. Following the termination of the 2012 Plan, awards may no longer be granted under the plan.

The 2012 Plan is administered by our Board, unless and until the board delegates administration to a committee, which shall determine the grantees of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary in the administration of the 2012 Plan. Awards under the 2012 Plan may be granted until ten years after the date on which the 2012 Plan was approved by our shareholders.

Options granted under the 2012 Plan are either incentive share options pursuant to Section 422 of the Internal Revenue Code or nonstatutory share options. Options generally vest as determined by the board or committee. Options, other than certain incentive share options described below, must have an exercise price not less than 100% of the fair market value of an underlying share on the date of grant. Options, other than certain incentive share options described below, that are not exercised within ten years from the grant date expire, unless otherwise determined by our Board or its designated committee, as applicable. Incentive share options granted to a person holding more than 10% of our voting power will expire within five years from the date of the grant and must have an exercise price at least equal to 110% of the fair market value of an underlying share on the date of grant. Unless otherwise provided in an option agreement, in the event of termination of employment or services for reasons of disability or death, the grantee, or in the case of death, his or her legal successor, may generally exercise options that have vested prior to termination within a period of one year from the date of disability or death (or the expiration of the term of the option, if earlier). If a grantee's employment or service is terminated for any other reason, the grantee may generally exercise his or her vested options within 90 days of the date of termination (or the expiration of the term of the option, if earlier).

Share appreciation rights are awards entitling a grantee to receive a payment representing the difference between the base price per share of the right and the fair market value of a share on the date of exercise subject to any terms or conditions as the board or committee may determine in the award agreement. Share appreciation rights are payable in cash, shares of equivalent value or a combination thereof.

Restricted share awards are ordinary shares that are awarded to a grantee subject to the satisfaction of the terms and conditions established by the board or committee in the award agreement. Until such time as the applicable restrictions lapse, restricted shares are subject to forfeiture and may not be sold, assigned, pledged or otherwise disposed of by the participant who holds those shares.

RSUs are awards covering a number of hypothetical units with respect to shares that are granted subject to such vesting and transfer restrictions and conditions of payment as the board or committee may determine. Restricted share units are payable in cash, shares of equivalent value or a combination thereof.

Performance share awards are awards denominated in shares which may be earned in whole or part upon attainment of performance goals or other vesting criteria as the board or committee may determine.

Performance units are awards covering a number of hypothetical units with respect to shares that may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the board or committee may determine. Performance units are payable in cash, shares of equivalent value or a combination thereof.

Awards under the 2012 Plan may be made subject to performance goals relating to one or more business criteria and may provide for a targeted level or levels of achievement.

In the event that any change is made to the shares without consideration to the company (through merger, consolidation, reorganization, recapitalization, share dividend or similar event), the class and number of shares available for issuance, maximum award limits and any outstanding awards under the 2012 Plan will be appropriately adjusted. In the event of a change in control, either (i) the surviving entity may assume and continue outstanding awards (or substitute similar awards) in all or in part or (ii) if the surviving entity does not assume and continue awards (or substitute similar awards), unvested awards will be forfeited and vested awards shall terminate if not exercised at or prior to the change in control. Notwithstanding the foregoing, in the event of a change in control, the board, in its discretion, may accelerate the vesting of any or all awards, in whole or in part.

#### *2012 Israeli Sub Plan*

The 2012 Israeli Sub Plan provides for the grant by us of awards pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance (the “Ordinance”) and the rules and regulations promulgated thereunder. The 2012 Israeli Sub Plan provides for options and share awards to be granted to our or our affiliates’ employees, directors and officers who are not “Controlling Shareholders,” as defined in the Ordinance, and who are considered Israeli residents, to the extent that such options or awards either are (i) intended to qualify for special tax treatment under the “capital gains track” provisions of Section 102(b)(2) of the Ordinance or (ii) not intended to qualify for such special tax treatment. The 2012 Israeli Sub Plan also provides for the grant of options under Section 3(i) of the Ordinance to our Israeli non-employee service providers and controlling shareholders, who are not eligible for such special tax treatment.

#### *2012 U.S. Sub Plan*

The 2012 U.S. Sub Plan applies to grants to participants who are citizens or residents of the United States on the date of grant of an award. Under the 2012 U.S. Sub Plan, the board may require a participant to represent that he or she is acquiring securities for investment purposes and without a view to distribution thereof. Shares will not be issued under the U.S. Sub Plan unless the issuance complies with the requirements of any stock exchange on which the shares are then listed or quoted, any securities or tax laws and all other applicable laws. All shares delivered under the U.S Sub Plan will be subject to such transfer orders and other restrictions as our Board may deem advisable under the rules, regulations, and other requirements of any stock exchange upon which the shares are then listed and any applicable laws. Our obligations under the U.S. Sub Plan will be conditioned on the payment by the participant of all applicable withholding taxes.

The U.S. Plan contains provisions relating solely to participants located in California, which generally provide that in the event of termination of employment or services for reasons of disability or death, the participant, or in the case of death, his or her legal successor, may generally exercise options that have vested prior to termination within a period of six months from the date of disability or death (or the expiration of the term of the option, if earlier). If a participant's employment or service is terminated for any other reason, the grantee may generally exercise his or her vested options within 30 days of the date of termination (or the expiration of the term of the option, if earlier).

### *2006 Stock Option Plan*

In November of 2006, we adopted our 2006 Stock Option Plan, which we refer to as the 2006 Plan. The 2006 Plan provides for the grant of stock options to our employees who are considered Israeli residents, members of our board or consultants. As of March 1, 2018, options to purchase 31,806 ordinary shares were outstanding under the 2006 Plan. The 2006 Plan was terminated on August 19, 2014, although option awards outstanding as of that date will continue in full force in accordance with the terms under which they were granted. In the event that any option shall for any reason expire or terminate without having been exercised, the shares not acquired shall revert to the 2014 Plan and again become available for issuance. Following the termination of the 2006 Plan, awards may no longer be granted under the plan.

The 2006 Plan is administered by our Board, unless the Board delegates administration to a committee, which determines the grantees of options and the types of options to be granted, approves the terms and conditions of options, exercises such powers and performs such acts necessary or expedient to promote the best interests of the company with respect to the 2006 Plan. Our Board may, at any time, amend, alter, suspend or terminate the 2006 Plan, but may not thereby impair the rights of any grantee without his or her consent.

The terms of options granted under the 2006 Plan are determined by the administrator and set forth in an option agreement. Such terms include the type of option, the term of the option, the exercise price and the vesting schedule. Unless otherwise stated in an option agreement, each option expired two years after our initial public offering in September 2014.

The 2006 Plan provides for treatment of options upon various terminations of employment or other service to the company, including the period for which the vested period of option can be exercised following termination and, in some cases (such as termination due to disability, death or retirement), the exercisability of the portion of the option that would have become vested on the next vesting date.

The number of shares covered by or underlying each outstanding option and the number of shares which have been authorized for issuance under the 2006 Plan shall be appropriately adjusted in the case of any increase or decrease in the number of issued shares resulting from a share split, reverse share split, recapitalization, combination or reclassification of the shares, rights issues or any other increase or decrease in the number of issued shares in each case effected without receipt of consideration by the company. In the event of a merger or acquisition, each outstanding option shall be assumed or an equivalent award substituted by the successor company or a parent or subsidiary of the successor company. In the event that the successor company refuses to assume or substitute outstanding options, such options shall be deemed fully exercisable upon the closing of the transaction. In the event of a voluntary liquidation which is not considered a merger or acquisition under the 2006 Plan, each grantee shall be notified and have the right to exercise the vested options within five days.





**Outstanding Equity Awards at Fiscal Year-End**

The following table sets forth information concerning outstanding equity awards as of December 31, 2017, for each Named Executive Officer:

Name	Grant Date(1)	Option Awards				Stock Awards
		Number of Securities Underlying Unexercised Options Exercisable (#)	Number of Securities Underlying Unexercised Options Unexercisable(#)	Option Exercise Price (\$)	Option Expiration Date	Number of Shares Units of Stock that Have Not V
Larry Jasinski	05/1/2012(14)	165,492	-	1.32	5/1/2022	
	05/10/2012(15)	82,728	-	1.32	5/10/2022	
	12/24/2013(16)	141,030	-	1.49	12/24/2023	
	06/27/2017(3)	-	125,000	2.1	06/27/2027	
	12/15/2014(4)					
	05/24/2016(5)					
	06/27/2017(6)					
	10/05/2017(7)					
Kevin Hershberger	04/18/2017(8)	-	103,500	2.0	04/18/2027	
	05/18/2016(9)					
	04/18/2017(10)					
	10/05/2017(7)					
Ofir Koren	07/17/2013(11)	1,890	-	1.32	07/17/2023	
	12/24/2013(12)	16,918	-	1.49	12/24/2023	
	04/18/2017(8)	-	37,500	2.0	04/18/2027	
	01/09/2015(13)					
	05/18/2016(9)					
	04/18/2017(10)					
	10/05/2017(7)					

(1) Represents grant dates of the stock option and RSU awards.

(2) The amount listed in this column represents the product of the closing market price of the Company's ordinary shares as of December 31, 2017 (\$1.10) multiplied by the number of shares subject to the award.



Option awards vest with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on June 27, 2018 (3) and thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on September 27, 2018 and ending on June 27, 2021.

RSUs vested with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on December 15, 2015 (4) and vested thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on March 15, 2015 and ending on December 15, 2018.

RSUs vested with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on May 24, 2017 and (5) vested thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on August 24, 2017 and ending on May 24, 2020.

RSUs vest with respect to 1/4<sup>th</sup> of the original number of shares on an annual basis commencing on June 27, 2018 (6) and ending on June 27, 2021.

RSUs vest with respect to 1/3<sup>rd</sup> of the original number of shares on an annual basis commencing on October 5, 2018 and ending on October 5, 2020. The RSUs were granted in connection with the cancellation of certain (7) underwater stock options as part of the Equity Exchange Program. For more information, see “—Equity Exchange Program.”

Option awards vest with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on April 18, 2018 (8) and thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on July 18, 2018 and ending on April 18, 2021.

RSUs vested with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on May 18, 2017 and (9) vested thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on August 18, 2017 and ending on May 18, 2020.

RSUs vested with respect to 1/4<sup>th</sup> of the original number of shares on an annual basis commencing on April 18, (10) 2018 and ending on April 18, 2021.

Option awards vested with respect to 1/48<sup>th</sup> of the original number of ordinary shares subject thereto on July 17, (11) 2014, and vested thereafter at a rate of 1/48<sup>th</sup> of the original number of shares on a monthly basis ending on June 1, 2017.

Option awards vested with respect to 1/48<sup>th</sup> of the original number of ordinary shares subject thereto on January (12) 24, 2014, and vest thereafter at a rate of 1/48<sup>th</sup> of the original number of shares on a monthly basis ending on December 1, 2017.

RSUs vested with respect to 1/4<sup>th</sup> of the original number of ordinary shares subject thereto on January 9, 2016 and (13) vest thereafter at a rate of 1/16<sup>th</sup> of the original number of shares on a quarterly basis commencing on April 9, 2016 and ending on January 9, 2019.

Option awards became vested and exercisable a rate of 1/12<sup>th</sup> the original number of ordinary shares subject (14) thereto on a quarterly basis commencing on May 1, 2012.

Option awards became vested and exercisable a rate of 1/12<sup>th</sup> the original number of ordinary shares subject (15) thereto on a quarterly basis commencing on May 10, 2012.

Option awards became vested and exercisable a rate of 1/48<sup>th</sup> the original number of ordinary shares subject (16) thereto on a quarterly basis commencing on January 23, 2014.

### **Potential Payments Upon Termination or Change in Control**

See “Executive Compensation—Employment Agreements.”

We have adopted, pursuant to shareholder approval, our Compensation Policy, which provides for certain benefits to our executive officers upon retirement or termination, whether or not in the event of a change in control. We may memorialize any of these benefits in arrangements we enter into with individual executive officers. Under the Compensation Policy, executive officers may be entitled to advance notice of termination of up to 12 months and to obtain up to 12 months of post-termination health insurance. In addition to receiving severance pay as required or facilitated under the local laws of the relevant jurisdiction, executive officers may have the right to receive up to 12 months of base salary and benefits, taking into account the period of the officer's service or employment, his or her performance during employment and contribution to the Company's targets and profits and the circumstances surrounding termination of his or her employment. These benefits are designed to attract and motivate highly skilled professionals to join our Company and to enable us in to retain key management.

### **Compensation Committee Interlocks and Insider Participation**

None of the members of the compensation committee is, or has ever been, an officer or employee of the Company or any of its subsidiaries. In addition, during the last fiscal year, no executive officer of the Company served as a member of the board of directors or the compensation committee of another entity that has one or more executive officers serving on the Company's compensation committee or the Board.

**EQUITY COMPENSATION PLAN INFORMATION**

The following table provides certain aggregate information with respect to our ordinary shares that may be issued under our equity compensation plans in effect as of December 31, 2017.

<b>Plan Category</b>	<b>Number of securities to be issued upon exercise of outstanding options, warrants and rights(1)(2)</b>	<b>Weighted-average exercise price of outstanding options, warrants and rights</b>	<b>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)(3)</b>
Equity compensation plans approved by security holders	1,846,797	1.86	1,301,521
Equity compensation plans not approved by security holders	—	—	—
Total	1,846,797	1.86	1,301,521

Represents shares issuable under our (i) 2014 Plan upon exercise of options outstanding to purchase 561,637 shares and upon the settlement of outstanding RSUs with respect to 569,071 shares, (ii) 2012 Equity Incentive Plan upon exercise of options outstanding to purchase 684,283 shares, and (iii) 2006 Stock Option Plan upon exercise of options outstanding to purchase 31,806 shares.

(2) The weighted average remaining term for the expiration of stock options is 6.33 years.

Represents shares available for future issuance under our 2014 Plan. The number of our ordinary shares reserved for issuance under the 2014 Plan is automatically increased each January 1 of each calendar year during the term of (3) the 2014 Plan by a number of shares equal to the lesser of: (x) 972,000, (y) 4% of the total number of shares outstanding on December 31 of the immediately preceding calendar year, and (z) an amount determined by our Board.

## **PROPOSAL TWO**

### **APPROVAL OF RSU GRANTS TO OUR DIRECTORS**

In 2014, our Compensation Committee, Board of Directors and shareholders approved equity compensation for all of our non-employee directors consisting of (i) a grant of options to purchase 12,546 ordinary shares upon each director's initial appointment, or, if not originally appointed by our Board, election, and (ii) thereafter, a grant of options to purchase 4,176 ordinary shares as of every annual general meeting following the director's initial election, provided that the director continues to serve on the Board of Directors following such annual general meeting. This equity compensation is in addition to the cash compensation paid to our directors, as described below under "Director Compensation." Such initial equity grant is intended to create an immediate long-term incentive for our newly-appointed or -elected non-employee directors and, along with annual grants, to ensure competitive compensation for non-employee directors as compared to similar issuers in our industry.

In evaluating our director compensation arrangements, our Board and Compensation Committee, with the assistance of Radford, our independent compensation consultant, determined that the equity compensation of our directors is significantly below that of our peer companies and no longer in line with industry practices or levels. Radford provided data on non-employee director compensation of peer companies in our industry on a global basis in 2017, which includes certain of our publicly-traded competitors described in "Part I. Item 1. Business—Competition" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. In order to ensure the Company's continued ability to attract and retain highly-qualified directors, our Compensation Committee and Board of Directors have approved an amendment to our director equity compensation arrangements, have determined that such amendment complies with our Compensation Policy and have recommended that shareholders approve this amendment.

Under the proposal, in addition to the cash compensation paid to our directors as described below under "Director Compensation," (i) each non-employee director who is first appointed or elected after March 1, 2018, upon his or her initial election or appointment will receive RSUs to purchase ordinary shares of the Company under the 2014 Plan (for purposes of this Proposal Two, reference to the 2014 Plan includes any other equity incentive plan as may be adopted by the Company and approved by our shareholders from time to time), with such RSUs to have a value based on the Black-Scholes model equal to \$30,000 on the date of grant, and (ii) each current and future non-employee director will receive, under the 2014 Plan, an annual grant of RSUs to purchase ordinary shares of the Company commencing with the 2018 annual general meeting of shareholders and at each annual general meeting thereafter (provided that such director continues to serve on the Board of Directors following such annual general meeting), having a value based on the Black-Scholes model equal to \$25,000 on the date of grant; All of the above grants of RSUs will vest on a quarterly basis over a period of one year from the date of their grant, with the vesting of such RSUs accelerated upon certain change of control events. The options and RSUs would otherwise be subject to the terms and conditions of the 2014 Plan and the non-employee director RSU award agreement in the form generally used by the Company at the relevant time, including any forms filed by the Company with the SEC.

If these amendments are not approved at the Meeting, the existing equity compensation arrangements for our non-employee directors will remain in place.

## **Proposed Resolution**

You are requested to adopt the following resolution:

“2. RESOLVED, to replace the Company’s current director equity compensation program with an equity compensation program containing the following elements:

“(a) a grant to each director (other than a director who is an employee of the Company) who is first appointed or elected after March 1, 2018, upon his or her initial election or appointment of RSUs to purchase ordinary shares of the Company, with such RSUs to have a value based on the Black-Scholes model equal to \$30,000 on the date of grant;

“(b) an annual grant of RSUs to each current and future director of the Company (other than a director who is an employee of the Company), commencing with the 2018 annual general meeting of shareholders and at each annual general meeting thereafter (provided that such director continues to serve on the Board of Directors following such annual general meeting), of RSUs to purchase ordinary shares of the Company, with such RSUs to have a value based on the Black-Scholes model equal to \$25,000 on the date of grant; and

“(c) all of the above grants of RSUs will vest in four equal quarterly installments starting three months from the date of grant, with the vesting of such RSUs to be accelerated upon certain change of control events in accordance with the Company’s standard policy, and will otherwise be governed by the 2014 Plan (or any other equity incentive plan as may be adopted by the Company and approved by our shareholders from time to time).”

## **Vote Required**

The affirmative vote of a majority of our ordinary shares voted in person or by proxy at the Meeting on the foregoing resolution is required to adopt the foregoing resolution.

## **Board Recommendation**



THE BOARD OF DIRECTORS RECOMMENDS A VOTE “**FOR**” THE ADOPTION OF THE FOREGOING RESOLUTION.

## THE TIMWELL TRANSACTIONS

### Background

Throughout 2017, our management and our Board continued to evaluate our available capital in view of general economic conditions and sought to raise financing by means of a strategic investment or partnership, joint venture or similar transaction. We received and examined various proposals from different strategic partners, and our management and Board considered various alternatives. After reviewing the available alternative structures and partners, including the outcome of calls and meetings with potential investors, our Board determined that it would be in the best interests of the Company and the shareholders that the Company negotiate a financing arrangement and strategic partnership, including a joint venture in China, with Timwell and certain of its affiliates, including RealCan Ambrum and Timwell China Parties. Our management continued to negotiate with Timwell and its affiliates regarding the terms of a private placement and strategic partnership. Throughout the negotiations, management reported to the Board.

In early March 2018, our Board approved the terms of an investment agreement and joint venture framework agreement, and on March 6, 2018, we entered into the agreements with Timwell and its affiliates.

### Investment Agreement

We entered into an investment agreement (the “Investment Agreement”), dated March 6, 2018, with Timwell, a Hong Kong corporation, pursuant to which we agreed, in return for aggregate gross proceeds to us of \$20 million, to issue to Timwell an aggregate of 16,000,000 of our ordinary shares, at a price per share of \$1.25. Timwell will make the investment in three tranches, consisting of \$5 million for 4,000,000 shares in the first tranche (the “First Tranche Closing”), \$10 million for 8,000,000 shares in the second tranche (the “Second Tranche Closing”) and \$5 million for 4,000,000 shares in the third tranche (the “Third Tranche Closing”). The \$5 million purchase price to be paid at the First Tranche Closing has been placed in escrow, and will be released upon shareholder approval of the transaction.

The First Tranche Closing is subject to the Company having received the approval by our shareholders of the transaction under Rule 5635 of Nasdaq and Israeli law. The Second Tranche Closing is subject to the conditions that, by July 1, 2018, (i) the Company and an affiliate of Timwell (as discussed below) will have formed the China JV (as defined below), and (ii) by no later than 20 days after the establishment of the China JV (or as soon thereafter as possible), the China JV and the Company will have executed the License Agreement and Supply Agreement (each as defined below). The Third Tranche Closing is subject to the conditions that, by April 1, 2019, (i) the Company will have provided to the China JV product documentation, component supply access, work instructions, know-how and

training, and will have defined quality system requirements necessary for rehabilitation using the Company's Restore product, and (ii) a China-based manufacturer or agent defined by the China JV will have successfully produced the Company's Restore product to the quality requirements defined by the Company. The Third Tranche Closing is expected to occur by December 31, 2018, before the April 2019 deadline under the Investment Agreement. The transaction is also subject to other customary closing conditions.

### ***Lock-up Period***

Until the earlier of 18 months following the Third Tranche Closing or the termination of the Investment Agreement, subject to limited exceptions, Timwell may not sell or transfer the ordinary shares purchased under the Investment Agreement (the “Purchased Shares”) except to its affiliates, unless a majority of the directors of our board of directors (the “Board”), excluding any member of our Board nominated or designated by Timwell, approves the transfer. Following this lock-up period, except for transfers of up to 10% of the shares to third parties who are not competitors of the Company, any sale or transfer of the Purchased Shares must be pursuant to Rule 144 under the Securities Act or an underwritten public offering. This restriction will terminate if any of the JV Agreement (as defined below), the License Agreement and the Supply Agreement is not executed within 12 months after the First Tranche Closing or is terminated. Timwell may also sell its Purchased Shares pursuant to any third-party tender offer for all of the Company’s ordinary shares.

### ***Board Appointment Rights***

Pursuant to the Investment Agreement, Timwell will be entitled upon the First Tranche Closing, and for so long as it maintains a 75% ownership of the Purchased Shares, to designate one nominee to our Board. Following the Third Tranche Closing and for so long as the shareholding requirements of the Purchased Shares above are satisfied, Timwell will be entitled to designate such aggregate number of members of the Board equal to the higher of (i) one, or (ii) the number of Board members affiliated with the Company’s next two largest shareholders at such time.

### ***Standstill and Voting Agreement***

Subject to certain limitations set forth in the Investment Agreement, Timwell has agreed not to acquire additional equity securities of the Company and has agreed to customary “standstill” arrangements, pursuant to which it will not take certain actions related to, or knowingly encourage others to take actions related to, business combinations, mergers, tender offers or restructurings, and will refrain from taking certain actions related to the calling of meetings, proxies, proposals, director nominations, voting trusts and other actions of shareholders. Timwell has also agreed to vote its ordinary shares in accordance with the recommendations of our Board on shareholder proposals and Board proposals relating to any change of control, election of directors, amendments to the Company’s organizational documents, director and officer compensation and certain other related matters, provided that the action does not have an disproportionate adverse impact on Timwell’s rights as a shareholder compared to the other shareholders.

Notwithstanding the above, pursuant to the Investment Agreement, Timwell will not be restricted from purchasing shares in open-market transactions after the Third Tranche Closing, so long as Timwell and its affiliates together

beneficially own not more than 35% of the outstanding shares of the Company. The standstill will remain in effect for so long as Timwell beneficially owns or has rights to at least 10% of the outstanding ordinary shares of the Company, and the voting agreement will remain in effect for so long as Timwell beneficially owns or has rights to at least 5% of the outstanding ordinary shares of the Company.

***Preemptive Rights***

The Investment Agreement grants Timwell certain preemptive rights. Following the First Tranche Closing and as long as Timwell holds at least 75% of the aggregate of the then-Purchased Shares at any of the First Tranche Closing, Second Tranche Closing and Third Tranche Closing through the date of determination of the preemptive right under the Investment Agreement, if any, in the event that the Company proposes to offer or sell any new securities other than in a public offering, the Company must first offer Timwell the right to purchase its then-applicable preemptive pro rata fraction of such new securities as calculated based on the terms provided in the Investment Agreement.

## **Registration Rights Agreement**

Pursuant to the Investment Agreement, upon the First Tranche Closing, the Company and Timwell will enter into the form of registration rights agreement attached as Annex A to the Investment Agreement (the “Registration Rights Agreement”), relating to registration under the Securities Act of resales of the Purchased Shares. Pursuant to the Registration Rights Agreement, Timwell and certain permitted transferees will have certain demand and piggyback registration rights with customary indemnification provisions, subject to customary cutbacks on the number of shares to be registered or offered in an underwritten offering where the managing underwriter advises that marketing factors call for a limitation on the number of shares to be registered or offered. The registration rights will terminate upon certain customary triggers, including when Timwell and certain permitted transferees could sell all of their Purchased Shares without restriction pursuant to Rule 144 under the Securities Act.

## **China JV, License Agreement and Related Agreements**

### *China JV*

Pursuant to terms of the joint venture framework agreement, dated March 6, 2018 (the “JV Framework Agreement”), between the Company and RealCan Ambrum Healthcare Industry Investment (Shenzhen) Partnership Enterprise (Limited Partnership), an affiliate of Timwell (“RealCan Ambrum”), the Company and RealCan Ambrum intend to form a joint venture company in China for the purposes of research and development, assembly, registration, import, operations, sales and marketing of the Company’s products in China (including Hong Kong and Macau) (the “China JV”). Under the JV Framework Agreement, the China JV will be owned 80% by RealCan Ambrum, other affiliates of Timwell (together with RealCan Ambrum, “Timwell JV Party”), and/or certain other related parties of Timwell and RealCan Ambrum to be agreed to by the parties in the JV Agreement (together with Timwell JV Party, “Timwell China Parties”) and 20% by the Company (which ownership by the Company will not be diluted for at least the first five years after the formation of the China JV).

The parties have agreed that they will collaborate to form the China JV by negotiating and signing a JV agreement (the “JV Agreement”), consistent with the terms of the JV Framework Agreement. Pursuant to the JV Framework Agreement, the Company will not compete with the China JV in China (including Macau and Hong Kong), and Timwell China Party will not compete with the Company anywhere in the world.

As set forth in the JV Framework Agreement, Timwell China Parties will appoint four of the China JV’s directors and the Company will appoint one director. The initial chief executive officer and the initial chief financial officer of the China JV will be appointed by joint agreement of Timwell China Parties and the Company. The Company will have

customary minority protection rights, including a requirement that board decisions on specified matters be unanimous, which will survive any public offering of the China JV to the extent permissible. There will also be restrictions in the JV Agreement on the parties' ability to sell or transfer their shares in the China JV other than to permitted transferees. Timwell China Parties and the Company will have a right of first refusal on proposed sales by the other party, and the Company will have a tag-along right if Timwell JV Party proposes to sell its shares in the China JV. Upon a change in control of the Company, Timwell China Parties will have the right to purchase the shares in the China JV owned by the Company at fair market value. In addition, each party will have the right to purchase the other party's shares, if the other party proposes to sell its shares to a competitor of the remaining party.

In order for the China JV to maintain exclusive rights in China (including Macau and Hong Kong) to market and sell the Company's products and the rights to the intellectual property, the China JV will be required to make certain minimum cash payments, to the Company of the following amounts: \$1.25 million for the first year after formation; \$4 million for the second year after formation; \$8 million for the third year after formation; an amount increased annually by 15% of the preceding year's amount for the fourth, fifth and sixth years after formation; an amount increased annually by 10% of the preceding year's amount for the seventh, eighth and ninth years after formation; and an amount increased between 5% and 8% of the preceding year's amount for the tenth year after formation onward.

The Company and Timwell (through the Timwell China Parties) have agreed to use reasonable best efforts to form the China JV, to negotiate and execute the JV Agreement on a date that allows reasonable time to ensure the establishment of the China JV no later than July 1, 2018, and to arrange for the China JV and the Company to execute and deliver the License Agreement and the Supply Agreement within 20 days after the establishment of the China JV.

### ***License Agreement***

In conjunction with and after formation of the China JV, the Company intends to execute a license agreement (the "License Agreement") with the China JV with terms and conditions consistent with an agreed set of key terms (the "License Key Terms"). Pursuant to the License Key Terms, the Company will grant to the China JV (a) an exclusive, royalty-bearing, non-sublicensable (except as mutually agreed or to the affiliates of Timwell China Parties), non-transferable (except as mutually agreed or to the affiliates of Timwell China Parties) license under certain of the Company's owned intellectual property, (b) an exclusive, royalty-bearing, non-sublicensable, non-transferable sublicense under certain of the Company's controlled (but not owned) patent rights and (c) a non-exclusive, non-sublicensable, non-transferable sublicense under certain of the Company's controlled (but not owned) know-how, in each case, solely for use for certain products in the China JV's business and only in China (including Hong Kong and Macau).

The term of the License Agreement will expire upon expiration of all valid claims of the licensed patents, subject to certain early termination events. The License Agreement will also be terminable by the Company or the China JV due to the other party's material uncured breach and for other events, including that sublicenses under any controlled (but not owned) intellectual property will terminate upon termination of the upstream license. The License Agreement will comply with and be expressly subject and subordinate to all requirements of any upstream license agreements and requirements of applicable law and will contain customary terms and conditions mutually agreed by the parties, including diligence, confidentiality, indemnity and limitation of liability provisions.



The Company and Timwell also intend for the China JV and the Company to enter into a supply agreement consistent with an agreed form of supply agreement (the “Supply Agreement”) pursuant to which the Company will sell its products to the China JV, for resale solely in China (including Macau and Hong Kong). The Supply Agreement will set a target profit margin for the Company on the sale of its products to the China JV, and also shall specify the credit terms to be afforded to the China JV on these sales. The China JV’s rights under the Supply Agreement are conditioned on specified performance fulfillment of the minimum cash payments as are specified in the JV Agreement (as described above). The term of the Supply Agreement will be concurrent with the term of the License Agreement, subject to termination provisions and other terms to be agreed to by the parties in the Supply Agreement.

*The Investment Agreement and JV Framework Agreement contain a number of representations and warranties that we and Timwell (and its affiliates) have made to each other that are customary in such transactions. Moreover, representations and warranties are frequently utilized in agreements as a means of allocating risks, both known and unknown, rather than to make affirmative factual claims or statements. These representations and warranties are made as of specific dates and are subject to important exceptions and limitations, including a contractual standard of materiality different from that generally applicable under federal securities laws. Accordingly, persons not party to the Investment Agreement or the JV Framework Agreement should not rely on the agreement for any characterization of factual information about us, Timwell or Timwell China Parties.*

*We believe that the issuance under each of the tranches described above will be exempt from registration under the Securities Act in reliance on Regulation S or pursuant to Section 4(a)(2) of the Securities Act regarding transactions by an issuer, in each case, involving offers and sales of securities outside the United States with no directed selling efforts made in the United States or not involving a public offering, respectively. Timwell represented its knowledge and financial sophistication as an investor and its intention to acquire the ordinary shares for investment only and not with a present view to, or in connection with, the distribution thereof. No general advertising or solicitation has been used in offering, or will be used in selling, the ordinary shares, and the shares were offered only to Timwell, a non-U.S. entity, in a transaction outside the United States.*

*This above description of the Investment Agreement and related transactions is not an offer to sell or a solicitation of offers to buy our ordinary shares. None of the ordinary shares to be issued to Timwell have been registered under the Securities Act, and such shares may not be offered or sold in the United States absent an effective registration statement or an exemption from the registration requirements under applicable federal and state securities laws.*

### **PROPOSAL THREE**

#### **APPROVAL OF THE ISSUANCE OF 16,000,000 ORDINARY SHARES IN A PRIVATE PLACEMENT TO TIMWELL, SUBJECT TO THE SATISFACTION OF CERTAIN CONDITIONS PRECEDENT, AS REQUIRED BY THE ISRAEL COMPANIES LAW AND NASDAQ RULE 5635(B)**

#### **Background**

As described above in “The Timwell Transactions,” the transactions with Timwell involve several different agreements with Timwell and its affiliates, including an Investment Agreement, JV Agreement (based on the already-signed JV Framework Agreement), Supply Agreement, License Agreement and Registration Rights Agreement (collectively, the “Timwell Agreements”). We are submitting to the approval of our shareholders at the Meeting only the issuance of 16,000,000 ordinary shares to Timwell under the Investment Agreement (the “Timwell Issuance”). The related terms of the Investment Agreement, including the transactions contemplated by the other Timwell Agreements, are not required to be submitted for shareholder approval. For information regarding the Investment Agreement under which we will make the Timwell Issuance, as well as the other Timwell Agreements not subject to shareholder approval, see “The Timwell Transactions” above.

#### **Shareholder Approval**

Shareholder approval of the Timwell Issuance is required pursuant to Nasdaq Rule 5635(b) and the Israel Companies Law.

#### ***Nasdaq Rule 5635(b)***

Our ordinary shares are currently listed for trading on the Nasdaq Capital Market. Pursuant to Nasdaq Rule 5635(b), shareholder approval is required prior to the issuance of securities when the issuance or potential issuance will result in a change of control of an issuer. For purposes of this rule, NASDAQ generally finds a change of control where (i) an issuance causes a shareholder or shareholder group to own or have the right to acquire 20% or more of the outstanding ordinary shares or voting power and (ii) this ownership or voting power would be the largest ownership position. On a post-transaction basis, based on 30,006,575 of our ordinary shares outstanding as of March 5, 2018 (excluding ordinary shares issuable upon conversion or exercise of derivative securities owned by other shareholders

or shares issued under our equity incentive plans, and assuming no changes otherwise to our capitalization), after each of the First Tranche Closing, the Second Tranche Closing and the Third Tranche Closing, Timwell will beneficially own 11.8%, 28.6% and 34.8% of our ordinary shares, respectively. As a result of the Timwell Issuance, Timwell will also have the Company's largest ownership position in terms of ownership and voting power, and will be entitled to certain board appointment rights as specified above under "The Timwell Transactions—Investment Agreement—Board Appointment Rights." Accordingly, we are seeking shareholder approval for the Timwell Issuance under Nasdaq Rule 5635(b).

Pursuant to the Investment Agreement, the price per share for each ordinary share to be acquired by Timwell at each tranche will be equal to \$1.25. This price exceeds the greater of the book value and market value (defined, pursuant to Nasdaq Rule 5005(a)(22), as the consolidated closing bid price per share) of our ordinary shares on the date that we and Timwell entered into the Investment Agreement. The Investment Agreement does not contain any price-based adjustment provisions.

### ***Israeli Law***

In addition, as an Israeli company we are subject to the Israel Companies Law. Under the Israel Companies Law, any acquisition of shares that results in a shareholder holding 25% or more of the voting rights in shareholder meetings generally must be made by means of (and subject to the rules and regulations regarding) a “special tender offer,” in which the offeror must purchase certain of such shares from the company’s shareholders. As discussed above, assuming no changes to our capitalization and no significant changes in the ownership of other large shareholders, the Timwell Issuance, following the Second Tranche Closing, will bring its ownership above the 25% level. This requirement would not apply if there were another 25% shareholder of the Company, but at this time there is no other shareholder of the Company that owns 25% or more of our ordinary shares. However, the Israel Companies Law also provides that the “special tender offer” rules and regulations do not apply to a transaction that is approved by the company’s shareholders as a private placement that will result in the investor’s holding 25% or more of the voting rights in shareholder meetings. Accordingly, we are seeking shareholder approval of the Timwell Issuance, so that the special tender offer rules under the Israel Companies Law will not apply to the transaction.

### **Reasons for the Timwell Issuance**

Our management and Board believe that the Timwell Issuance, along with the related transactions contemplated in the other Timwell Agreements, lies in the best interests of the Company and its shareholders for various reasons.

### ***The Timwell Issuance Will Provide us with Financing to Pursue Critical Growth Initiatives and Enhance our Capital Position***

The proposed transaction will equip us with significant financing of \$20.0 million (subject to the satisfaction of specified closing conditions for each of the three tranches), which we believe will improve our future capital position, support key endeavors toward growth and increase our Company’s value. While we continue to improve and market our ReWalk exoskeleton, prepare for prospective clinical testing on our in-development Restore system for stroke patients, and develop for ultimate commercialization a lightweight soft suit exoskeleton for individuals with other lower limb disabilities, we confront significant cash needs. Additionally, because we generate significant revenues from third-party payors, we require capital to fund continued collaboration with both national and regional commercial insurance companies, health care practitioners, physicians, researchers and the spinal cord injury community. In particular, our anticipated primary uses of cash are (i) sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage, and (ii) R&D costs related to, in the shorter term, our Restore device that will assist stroke patients, and, in the longer term, developing our next generation of ReWalk with design improvements and products that address other medical indications such as cerebral palsy, Parkinson’s disease and elderly assistance.

Since inception, we have funded our operations primarily through the sale of securities in the capital markets and the incurrence of bank debt. An inability to meet various capital requirements could impair our efforts to conceptualize, design, bring to market and enhance both existing and innovative new products, retain talented employees and continue leveraging our reimbursement work with national and regional commercial insurance companies both in the United States and abroad. For more information, see “Part I. Item 1A. Risk Factors” and “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. The proceeds of the Timwell Issuance represent a critical source of capital for the Company, which we believe will enable us to pursue initiatives that enhance our financial performance and return value to shareholders.

***The Timwell Issuance Will Facilitate our Cooperation with Timwell Affiliates in China via the China JV***

The Timwell Issuance is directly tied to the establishment and operation of the China JV, both as a contractual and practical matter. The China JV will initially focus on development, production and marketing of ReWalk's Restore soft-suit exoskeleton for stroke patients in a rehabilitation setting, followed by commercialization of ReWalk's spinal cord injury products for community and rehabilitation use. For more information, see "The Timwell Transactions" above. Thus, by way of the related China JV, the Timwell Issuance will provide us with important access to the market in China, which we believe could serve as a major market for our products. The China JV, to the extent formed, will enable us to expand the planned launch of the Restore soft suit exoskeleton in the United States and Europe to China. It will also allow us to serve a significant stroke population in China and otherwise establish our presence in the Chinese market, promoting our financial condition and bringing value back to our shareholders.

***The Timwell Issuance May Position Timwell as a Long-Term Shareholder with a Deeply Vested Interest in our Success***

We believe that the structure of the Timwell Issuance will establish Timwell as a committed long-term strategic investor in the Company. As described in "The Timwell Transactions," the issuances will occur in three tranches, which will close upon the achievement by us and Timwell of various milestones, followed by an 18-month lock-up period on transfers (subject to certain exceptions). Timwell will also have registration rights pursuant to the Registration Rights Agreement. All capital funding for the China JV will be supplied by Timwell China Party, with ReWalk contributing the technology, and Timwell China Party will possess a majority interest in the China JV. This staggered, extended structure, which prevents a short-term exit and immerses Timwell in our expansion efforts, is aimed to incentivize Timwell and its affiliates to place resources in our Company, ultimately watching the value of our Company grow and reap the benefits of its investments. We believe that engaging with investors that have serious interests in the long-term success of our Company advantages all shareholders.

**Use of Proceeds**

We intend to use the net proceeds from the Timwell Issuance (i) primarily for (a) sales, marketing activities related to market development in our existing markets as well as expanding into China, and reimbursement expenses related to market development activities and broadening third-party payor coverage and (b) research and development costs related to developing our lightweight "soft suit" exoskeleton technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk, and (ii) the remainder for general corporate purposes. We will have broad discretion in the way we use the net proceeds of the Timwell Issuance.



### **Interests of the Company’s Directors, Executive Officers and Their Associates in the Proposal**

As a result of the Timwell Issuance, the Company’s current and former directors, executive officers and their associates (as defined in Rule 14a-1 under the Exchange Act) will not receive any extra or special benefit not shared on a pro rata basis by all other holders of the ordinary shares.

### **Possible Effects of Approval and Non-Approval of the Timwell Issuance on the Company’s Shareholders**

If the Timwell Issuance is approved, 16,000,000 ordinary shares will be issued to Timwell, subject to the satisfaction of specified conditions precedent. As discussed above under “Material Terms of Timwell Private Placement and Shareholder Approval—Shareholder Approval,” if such conditions are met at any or all of the three tranche closings, our existing shareholders will experience substantial incremental dilution, which will significantly diminish the value and voting power of our shareholders’ investment in our ordinary shares. Additionally, Timwell has agreed to customary “standstill” restrictions and to vote its ordinary shares in accordance with the recommendation of our board on certain matters, provided it maintains a certain percentage of beneficial ownership in our ordinary shares. Based on its board representation and significant ownership position, Timwell will, after each of the various closings, alone possess sufficient voting power to influence significantly, or potentially have de facto control over, the outcome of key matters requiring shareholder approval. For more information, see “Part I. Item 1A. Risk Factors—Risks Related to the Timwell Investment Agreement and Related Transactions” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

If shareholders do not approve the Timwell Issuance, our management will be required to divert attention from our business and negotiate similarly-sized financing with another investor, which may be difficult to do on terms favorable to the Company and its shareholders. The failure to close any of the three tranches under the Timwell Issuance could also, among other things, adversely impact our liquidity and financial condition, continue to raise issues regarding our ability to continue as a going concern and affect our ability to regain compliance with quantitative Nasdaq continued listing standards as of March 30, 2018 (to the extent that we would show Nasdaq the effect of the Timwell Issuance subsequent to March 30, 2018 on a pro forma basis). For more information on these and other risks relating to our financial condition, see “Part I. Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

### **Proposed Resolution**

You are requested to adopt the following resolution:



“3. RESOLVED, that (a) the issuance of 16,000,000 ordinary shares, par value NIS 0.01 per share, of the Company in a private placement to Timwell Corporation Limited (“Timwell”), subject to the satisfaction of conditions precedent specified in the Investment Agreement, dated March 6, 2018, between the Company and Timwell (the “Timwell Issuance”), be approved, ratified and authorized in all respects, (b) the Timwell Issuance shall be deemed, for purposes of the Israel Companies Law, as a private placement that will result in Timwell holding 25% or more of the voting rights in shareholder meetings of the Company, and this approval is thus given for all purposes under the Israel Companies Law, and (c) the Timwell Issuance will result in a change of control under Rule 5635(b) of The NASDAQ Stock Market LLC (“Nasdaq Rule 5635(b)”), and this approval is thus given for all purposes under Nasdaq Rule 5635(b).”

### **Vote Required**

The affirmative vote of a majority of our ordinary shares voted in person or by proxy at the Meeting on the foregoing resolution is required to adopt the foregoing resolution.

### **Board Recommendation**

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “**FOR**” THE ADOPTION OF THE FOREGOING RESOLUTION.

## **PROPOSAL FOUR**

### **REAPPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

#### **Background**

Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, served as our independent registered public accounting firm for the year ended December 31, 2017. At the Meeting, shareholders will be asked to approve the reappointment of Kost Forer Gabbay & Kasierer as our independent registered public accounting firm for the year ending December 31, 2018 and until the next annual meeting of shareholders and to authorize the Board, upon the recommendation of the audit committee, to fix the remuneration of the independent registered public accounting firm in accordance with the volume and nature of its services. Representatives of Kost Forer Gabbay & Kasierer are not expected to be present at the Meeting and are not expected to be available to respond to questions, and will not have the opportunity to make a statement.

We have been advised by Kost Forer Gabbay & Kasierer that it is an independent registered public accounting firm with the PCAOB, and complies with the auditing, quality control and independence standards and rules of the PCAOB.

In executing its responsibilities, the audit committee engages in an annual evaluation of Kost Forer Gabbay & Kasierer's qualifications, performance and independence, and considers whether continued retention of Kost Forer Gabbay & Kasierer as the Company's independent registered public accounting firm is in the best interest of the Company. The audit committee is also involved in the selection of Kost Forer Gabbay & Kasierer's lead engagement partner. While Kost Forer Gabbay & Kasierer has been retained as the Company's independent registered public accounting firm continuously since the Company's initial public offering in September 2014, in accordance with SEC rules and Kost Forer Gabbay & Kasierer policies the firm's lead engagement partner rotates every five years. In assessing independence, the audit committee reviews the fees paid, including those related to non-audit services. As a result of its evaluation of Kost Forer Gabbay & Kasierer's qualifications, performance and independence, the Audit Committee and the Board of Directors believe that the continued retention of Kost Forer Gabbay & Kasierer to serve as the Company's independent registered public accounting firm for the year ending December 31, 2018 is in the best interests of the Company and its shareholders. While the audit committee retains Kost Forer Gabbay & Kasierer as our independent registered public accounting firm, the Board of Directors is submitting the selection of Kost Forer Gabbay & Kasierer to the shareholders for ratification upon the recommendation to do so by the audit committee.

Unless contrary instructions are given, shares represented by proxies solicited by the Board will be voted for the ratification of the selection of Kost Forer Gabbay & Kasierer as our independent registered public accounting firm for the year ending December 31, 2018. If the selection of Kost Forer Gabbay & Kasierer is not ratified by the shareholders, the audit committee will reconsider the matter. Even if the selection of Kost Forer Gabbay & Kasierer is ratified, the audit committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change is in our best interests.

### Principal Accounting Fees and Services

The following table sets forth, for each of the years indicated, the fees expensed by Kost Forer Gabbay & Kasierer, our independent registered public accounting firm, in each such year.

	2016	2017
	(\$ in thousands)	
Audit Fees <sup>(1)</sup>	\$ 350	\$ 306
Audit-Related Fees <sup>(2)</sup>	-	\$ 10
Tax Fees <sup>(3)</sup>	\$ 46	\$ 19
All Other Fees <sup>(4)</sup>	\$ 6	\$ 33
<b>Total:</b>	<b>\$ 402</b>	<b>\$ 368</b>

“Audit fees” include fees for services performed by our independent public accounting firm in connection with our annual audit for 2016 and 2017, fees related to the filing of our registration statements on Form F-3 and Form S-3, (1) fees related to our at-the-market equity offering program and follow-on offering of ordinary shares and warrants and fees for consultation concerning financial accounting and reporting standards.

“Audit-related fees” relate to assurance and associated services that are traditionally performed by an independent (2) auditor, including accounting consultation and consultation concerning financial accounting, reporting standards and due diligence.

“Tax fees” include fees for professional services rendered by our independent registered public accounting firm for (3) tax compliance, transfer pricing and tax advice on actual or contemplated transactions.

“All other fees” include fees for services rendered by our independent registered public accounting firm with respect (4) to government incentives and other matters.

### Audit Committee’s Pre-Approval Policies and Procedures

The audit committee has adopted a pre-approval policy for the engagement of our independent accountant to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit service, audit-related service and tax services that may be performed by our independent accountants.

All engagements by us of the auditors for 2016 and 2017 were pre-approved by the audit committee.

**Proposed Resolution**

You are requested to adopt the following resolution:

“4. RESOLVED, that the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2018 and until the next annual meeting of shareholders be approved, and that the Board, upon recommendation of the audit committee, be authorized to fix the remuneration of said independent registered public accounting firm in accordance with the volume and nature of their services.”

### **Vote Required**

The affirmative vote of a majority of our ordinary shares voted in person or by proxy at the Meeting on the foregoing resolution is required to adopt the foregoing resolution.

### **Board Recommendation**

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “**FOR**” THE ADOPTION OF THE FOREGOING RESOLUTION.

## **CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE**

### **Director Independence**

See “Corporate Governance—Director Independence.”

### **Certain Relationships and Related Transactions**

See “Executive Compensation—Narrative Disclosure to the Summary Compensation Table—Employment Agreements” for a description of employment agreements between us and the Named Executive Officers.

See “Corporate Governance - Approval of Related Party Transactions Under Israeli Law” for a discussion of our policies and procedures related to related party transactions and conflicts of interest. We describe below transactions and series of similar transactions which are currently proposed or to which we have been or were a party since January 1, 2016, in which (a) the amount involved exceeds or exceeded \$120,000 and (b) any of our directors, director nominees, executive officers, beneficial owners of more than 5% of our ordinary shares, or any affiliates or members of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest. Although we do not have a formal written policy as to the approval of related party transactions, all related party transactions for which disclosure would be required under Item 404 of Regulation S-K are approved based on

procedures under Israeli law, as is duly memorialized in the minutes of the meetings of the Board and audit committee, as applicable.

***Series E Preferred Securities Purchase Agreement***

On June 26, 2014, we entered into a Securities Purchase Agreement with entities affiliated with Vitalife and other entities that no longer beneficially own more than 5% of our outstanding ordinary shares (the "Series E SPA"). The price per share of our Preferred E Shares reflected in the Series E SPA had been set forth in a non-binding term sheet dated June 9, 2014, prior to our receipt of Food and Drug Administration clearance to market ReWalk Personal in the United States. The transaction closed in July 2014. At the time we entered into the Series E SPA, certain parties thereto, including entities affiliated with SCP Vitalife Partners II and other entities held our preferred shares and warrants to purchase our preferred shares.

Pursuant to the Series E SPA, we issued an aggregate of 75,695 of our Preferred E Shares and warrants to purchase an aggregate of 37,850 Preferred E Shares to investors named in the Series E SPA for an aggregate purchase price in cash of \$13.0 million (which were later adjusted). The Preferred E Shares were issued at a price of \$171.74 per share. The warrants have an exercise price of \$10.08 per share and are exercisable until four years from date of grant, subject to certain adjustments.

Additionally, our pre-IPO Articles of Association provided for anti-dilution protections to certain pre-IPO holders of our preferred shares based on the IPO price. As a result, for no additional consideration, we issued an additional 203,580 ordinary shares to such certain shareholders.

***Amended and Restated Shareholders' Rights Agreement***

On July 14, 2014, in connection with our series E financing round completed in June 2014, we entered into an Amended and Restated Shareholders' Rights Agreement, (the "Shareholders' Rights Agreement"), with entities affiliated with SCP Vitalife Partners II (the "Vitalife Entities"), Yaskawa Electric Corporation ("Yaskawa"), and other entities and shareholders that no longer beneficially own more than 5% of our outstanding ordinary shares or are otherwise no longer related parties. The Shareholders' Rights Agreement provides the shareholders party to it holding Registrable Securities (as defined below) (the "Significant Shareholders") with the registration rights described below.

*Form S-1 or Form F-1 Demand Rights.* Subject to any lock-up agreements entered into by holders of registration rights, upon the written request of the requisite holders, we are required to file a registration statement on Form S-1 or Form F-1 with respect to the Registrable Securities (as defined below) requested to be included in the registration statement. Following a request to effect such a registration, we are required to give notice of the request to the other Significant Shareholders and offer them an opportunity to include their Registrable Securities in the registration statement. "Registrable Securities" means, subject to certain customary exceptions, (i) our ordinary shares that were issued upon conversion of our preferred shares, (ii) shares issued in respect of shares referred to in (i) and (ii) above and (iii) any shares issued pursuant to a share split, combination thereof or other similar recapitalization with respect to any of the shares described in clauses (i), (ii) or (iii) above.

*Form F-3 and Form S-3 Demand Rights.* As long as we are eligible under applicable securities laws to file a registration statement on Form S-3, or if we are eligible to file on Form F-3, upon the request of any holder of our ordinary shares that were preferred shares prior to our IPO, we will be required to file a registration statement on Form S-3 or Form F-3, as applicable, in respect of such Registrable Securities. Following a request to effect such a registration, we will be required to give notice of the request to the other Significant Shareholders and offer them an opportunity to include their Registrable Securities in the registration statement. We will not be required to effect an offering pursuant to a registration statement on Form S-3 or Form F-3 more than twice in any 12-month period and are only required to do so if the aggregate proceeds from any such offering are estimated in good faith to be in excess of \$1.0 million.

*Piggyback Registration Rights.* Holders of Registrable Securities have the right to request that we include their Registrable Securities in any registration statement filed by us in the future for the purposes of a public offering by us or any other person other than holders of Registrable Securities, subject to specified exceptions.

*Cutback.* In the event that the managing underwriter of shares to be distributed pursuant to a demand registration or in connection with a piggyback registration advises holders of Registrable Securities that marketing factors require a limitation on the number of shares that can be included in the offering, Registrable Securities will be included in the registration statement in an agreed order of preference among the holders of registration rights.



*Termination.* All registration rights described above will terminate on the fifth anniversary of the closing of our initial public offering.

*Expenses.* We will pay all expenses in carrying out the foregoing registrations other than selling shareholders' underwriting discounts and commissions and transfer taxes.

*Agreements with Yaskawa*

On September 24, 2013, we entered into a Strategic Alliance Agreement with Yaskawa. Pursuant to the Strategic Alliance Agreement, we and Yaskawa will collaborate in the following areas, among others:

marketing, distribution and commercialization of our products by Yaskawa, subject to a separate distribution agreement;

marketing and distribution of future Yaskawa healthcare equipment products by us in the scope of our sales network; and

improvement and quality control of our products by applying Yaskawa's know-how and expertise in motion control and robotics.

The Strategic Alliance Agreement also provides for the creation of a joint steering committee to meet quarterly to review, among other things, sales targets for our products by Yaskawa, opportunities for us to sell Yaskawa products, possibilities for quality improvements to our products by applying Yaskawa's expertise and future research and development for our products. In the future, subject to any necessary regulatory clearance, we are entitled to market and sell certain of Yaskawa's products currently under development, which consist of complementary products to the ReWalk, in the United States and Europe. While the terms of any such arrangement, including with respect to any compensation we may receive, have not yet been agreed, we expect that any such compensation would take the form of a percentage discount off of each product's list price or another customary arrangement. The term of the agreement is ten years, but it may be terminated by either party after seven years or upon 60 days' notice in the event of an uncured default under the agreement.

On September 24, 2013, we and Yaskawa also entered into an Exclusive Distribution Agreement which provides that Yaskawa will be our exclusive distributor in Japan, China (including Hong Kong and Macau), Taiwan, South Korea, Singapore and Thailand. In addition, if we desire to sell any exoskeleton products into any regional market in the Asian and Pacific regions (other than Australia, New Zealand or India), Yaskawa will have a right of first refusal to serve as distributor in those markets, subject to an agreement on minimum purchase requirements. In addition, if we offer better pricing to any other distributor than what we offer Yaskawa, Yaskawa will be entitled to that pricing. The initial term of the Exclusive Distribution Agreement is ten years. Either party may terminate the agreement upon 90 days' written notice after seven years or upon an event of default under the agreement or a bankruptcy event of the other party. In connection with the closing of the first tranche of the private placement of the Investment Agreement with Timwell, we are required to amend our exclusive distribution agreement with Yaskawa to terminate the distribution rights granted to Yaskawa in China (including Hong Kong and Macau). Yaskawa has agreed in principle to such amendment, and we expect that a formal amendment agreement will be executed prior the closing of the first tranche of the private placement of the Investment Agreement with Timwell. Through December 30, 2017, Yaskawa had paid us an aggregate of approximately \$1,024,000 pursuant to the exclusive distribution agreement, \$588,000 of which was paid since January 1, 2016.



*Agreements with Kreos V*

On December 30, 2015, we entered into the Kreos V Loan Agreement with Kreos V, pursuant to which Kreos V extended a line of credit to us in the amount of \$20.0 million. In connection with the Kreos V Loan Agreement, we issued to Kreos V a warrant to purchase up to 119,295 ordinary shares at an exercise price of \$9.64 per share, which was increased to represent the right to purchase up to 167,012 ordinary shares on December 28, 2016. On June 9, 2017, we entered into the first amendment of the Kreos V Loan Agreement, under which \$3.0 million of the outstanding principal is extended and subject to the terms of the Kreos V Convertible Note, convertible into up to 2,523,660 ordinary shares (subject to customary anti-dilution adjustments in connection with a share split, reverse share split, share dividend, combination, reclassification or otherwise). This amount includes (i) 2,365,931 ordinary shares issuable upon conversion of the \$3.0 million at \$1.268 per share and (ii) 157,729 ordinary shares issuable upon conversion of “end of loan payments” totaling \$200,000 at \$1.268 per share. Pursuant to the Kreos V Loan Agreement, we are required to pay Kreos V “end of loan payments” equal to 1.0% of the amount of each tranche drawn down upon the expiration of each such tranche. Because the aggregate amount we drew down under the Kreos V Loan Agreement equals \$20,000,000, the total “end of loan payments” equal \$200,000. All amounts are convertible at any time until the earlier of (i) the maturity date of June 9, 2020 or (ii) a “Change of Control,” as defined in the Kreos V Loan Agreement. In lieu of receiving the “end of loan payments,” Kreos V may also require us to pay, upon conversion of the Kreos V Convertible Note, in whole or in part, an amount equal to 1% of the principal amount so converted and on the maturity date of June 9, 2020, we must pay to Kreos, in addition to the then-outstanding principal amount, an amount equal to 1% of the then-outstanding principal amount.

In the Kreos V Convertible Note, we undertook to prepare and file with the SEC (within five months of June 9, 2017) a registration statement on Form S-3 to enable the resale by the Kreos V, from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, of the ordinary shares to be issued upon conversion of the Kreos V Convertible Note, except shares that have been or could otherwise be freely sold using Rule 144 under the Securities Act. We also agreed to use commercially reasonable efforts to cause the registration statement to become effective as soon as reasonably practicable after we file it. In November 2017, Kreos V waived these registration rights until February 28, 2018, subject to certain exceptions. For more information on these agreements with Kreos V, see Note 6 to our audited consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. We may in the future choose to refinance up to a substantial portion of our remaining indebtedness under the Kreos V Loan Agreement, including by tying our repayment obligations and amortization schedule to the achievement of certain business milestones, which we have considered with Kreos V from time to time.

### *Agreements with Directors, Officers and Others*

#### *Consultant Agreement with Former Executive Officer*

As previously reported, John Hamilton stepped down as Vice President, Regulatory and Clinical effective January 31, 2017. Afterward, Mr. Hamilton agreed to serve as an outside consultant, pursuant to a consultant agreement (the “Consultant Agreement”), dated January 30, 2017, between Mr. Hamilton and the Company. Under the Consultant Agreement, Mr. Hamilton must use his best efforts to perform the consulting services and may receive both flat-rate fees and fees commensurate to certain pre-established performance levels. Since we and Mr. Hamilton entered into the Consultant Agreement, the amounts payable to Mr. Hamilton include \$255,642 in consulting fees, \$23,894 expense reimbursement and \$24,659 in medical and dental payments pursuant to the Consultant Agreement.

The term of the Consultant Agreement, initially set to expire on December 31, 2017, was extended by the parties on February 2, 2018, until December 31, 2018. Pursuant to this amendment, the maximum number of hours per month Mr. Hamilton may work without prior written authorization from the Company was changed from 120 to 60. Additionally, the parties may agree to extend the agreement at any time, and the Company may terminate the agreement upon 90 days’ written notice. Upon termination, Mr. Hamilton will not be entitled to any compensation other than that due and payable at termination, and, pursuant to the terms of our equity incentive plans, Mr. Hamilton’s right to exercise stock options will terminate. The Consultant Agreement contains solicitation and non-competition covenants (each of which remains in effect for 12 months following termination of the agreement) and confidentiality, trade secrets and inventions clauses.

#### *Employment Agreements*

We have entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. We have also entered into customary non-competition, confidentiality of information and ownership of inventions arrangements with our executive officers. However, the enforceability of the noncompetition provisions may be limited under applicable law.

#### *Options*

Since our inception we have granted options to purchase our ordinary shares to our officers and certain of our directors. Such option agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option plans under “Equity Compensation Plan Information.”

*Exculpation, Indemnification and Insurance*

Our Articles of Association permit us to exculpate, indemnify and insure certain of our office holders to the fullest extent permitted by the Israel Companies Law. We have entered into indemnification agreements with our office holders, exculpating them from a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted by law, subject to certain exceptions, including with respect to liabilities resulting from our initial public offering to the extent that these liabilities are not covered by insurance.

## **SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Section 16(a) of the Exchange Act requires that the Company's directors, executive officers and persons who own more than 10% of our outstanding ordinary shares (collectively, the "Section 16 insiders") file with the SEC initial reports of ownership in our ordinary shares and reports of changes in ownership in our ordinary shares. Based solely on a review of copies of such forms furnished to us and certain of our internal records, or upon written representations from officers, directors and greater than ten percent beneficial owners that no Form 5 was required, we believe that during the fiscal year ended December 31, 2017, all Section 16(a) filing requirements applicable to our directors, officers and greater than ten percent beneficial owners were satisfied on a timely basis, except as follows:

- (i) Mr. Jasinski filed a Form 4 on March 20, 2017 to report a disposition of ordinary shares on March 15, 2017 in connection with tax withholding obligations, due to an inadvertent administrative error.
- (ii) Mr. Koren filed a Form 4 on March 30, 2017 to report the exercise of certain stock options and the open market sale of the shares underlying such options on both January 3, 2017 and January 6, 2017.

(iii) Kreos V did not file a Form 3 following the closing of the Kreos V Convertible Note to report that, as a result of acquiring such note on June 9, 2017, it became a greater than ten percent beneficial owner and that it already owned warrants to purchase ordinary shares.

## **REVIEW OF THE COMPANY'S FINANCIAL STATEMENTS FOR 2017**

At the Meeting, the Board will provide a management report which will include a discussion of the Company's consolidated financial statements for the year ended December 31, 2017. This item does not require a vote of the Company's shareholders.

## **PROPOSALS OF SHAREHOLDERS AT 2019 ANNUAL MEETING**

Shareholder proposals intended to be included in our proxy materials for and voted on at our 2019 annual general meeting of shareholders ("2019 AGM") pursuant to Rule 14a-8 under the Exchange Act ("Rule 14a-8") must be received on or before November 26, 2018, by us at our principal executive offices located at ReWalk Robotics Ltd., 3 Hatnufa Street, Floor 6, P.O.B. 161, Yokneam Ilit 20692, Israel, Attention: Chief Financial Officer. Rule 14a-8 and other SEC proxy regulations govern the submission of shareholder proposals and our consideration of them for inclusion in the proxy materials for the 2019 AGM.

Additionally, pursuant to the requirements of Israeli law and our Articles of Association, any shareholder of ReWalk who intends to present a proposal at the 2019 AGM (including to nominate a director candidate not named in such proxy statement) outside the procedures in Rule 14a-8 must hold at least 1% of our outstanding voting power. Proposals must be received by us on or before November 26, 2018. However, if the date of the 2019 AGM changes by more than 30 calendar days before or after April 30, 2019, we must receive the written proposal by the earlier of (i) the seventh calendar day after the day on which we call and provide notice of the 2019 AGM and (ii) the fourteenth calendar day after the day on which we first publicly disclose the 2019 AGM. All shareholder proposals must be sent to ReWalk Robotics Ltd., 3 Hatnufa Street, Floor 6, P.O.B. 161, Yokneam Ilit 20692, Israel, Attention: Chief Financial Officer, be appropriate for consideration by shareholders at a meeting, and be made in the manner set forth in Article 22(c) of our Articles of Association and in accordance with the provisions of the Israel Companies Law. Shareholder proposals for the nomination of directors must also include certain additional information, the consent of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that (i) there is no limitation under the Israel Companies Law preventing the election of the nominees(s) and (ii) all of the information that is required to be provided to us in connection with such election under the Israel Companies Law and under our Articles of Association has been provided. The foregoing provisions do not affect a shareholder's ability to request inclusion of a proposal in our proxy statement within the procedures and deadlines set forth in Rule 14a-8, as cited in the paragraph above.

#### OTHER BUSINESS

The Board knows of no other matter to come before the Meeting. However, if any matters requiring a vote of the shareholders arise, it is the intention of the persons named in the attached form of proxy to vote such proxy in accordance with their best judgment, including any matters or motions dealing with the conduct of the Meeting.

Your prompt action is required to vote. Therefore, whether or not you expect to attend the Meeting, please complete and sign a form of proxy and return it to us, so that it is received at our offices no later than 5:00 p.m. (Israel time) on April 29, 2018.



## ADDITIONAL INFORMATION

### Householding of Proxies

As permitted under the federal securities laws, we or brokers holding shares on behalf of our shareholders will send a single set of our proxy materials, including this Proxy Statement and our annual report on Form 10-K for the year ended December 31, 2017, to multiple shareholders sharing an address who have requested that we mail them such materials. Each such shareholder will continue to receive a separate proxy card or voting instruction card and will retain a separate right to vote on all matters presented at the Meeting. This practice, known as “householding,” reduces duplicate mailings, thus saving printing and postage costs as well as natural resources. Once a shareholder receives notice from the shareholder’s broker or from us that communications to the shareholder’s address will be “household,” householding will continue until the shareholder is notified or until the shareholder provides contrary instructions. Shareholders whose households have received a single set of our proxy materials but who would like to receive additional copies of the materials may contact our transfer agent, American Stock Transfer & Trust Company, LLC, by telephone at 1-800-937-5449 or by mail at 6201 15<sup>th</sup> Avenue, Brooklyn, N.Y. 11219, and we will promptly deliver additional copies. Shareholders who do not wish to participate in “householding” and would like to receive their own sets of our proxy statement in future years, or who share an address with another shareholder of the Company and who would like to receive only a single set of our proxy statements should follow the instructions below.

Shareholders whose shares are registered in their own name should contact American Stock Transfer & Trust Company by telephone at 1-800-937-5449 or by mail at 6201 15<sup>th</sup> Avenue, Brooklyn, N.Y. 11219, and inform it of their request; and

Shareholders whose shares are held by a broker or other nominee should contact the broker or other nominee directly and inform them of their request.

### Annual Report on Form 10-K for 2017

Our Annual Report on Form 10-K for the year ended December 31, 2017, which includes our audited financial statements and related footnotes, and the exhibits filed with it are available at our website at <http://ir.rewalk.com>. **Upon written request by any shareholder to our Chief Financial Officer at 3 Hatnufa Street, Floor 6, Yokneam Ilit 2069203, Israel, we will furnish, without charge, a copy of our Annual Report on Form 10-K for the year ended December 31, 2017, including the financial statements and the related footnotes. The Company’s copying costs will be charged if exhibits to our Annual Report on Form 10-K for the year ended December 31, 2017 are requested.**

## **Incorporation by Reference**

The SEC allows us to “incorporate by reference” information into this Proxy Statement, which means that we can disclose important information to you by referring you to other documents that we have filed separately with the SEC and are delivering to you with the copy of this Proxy Statement. The information incorporated by reference is deemed to be part of this Proxy Statement. This Proxy Statement incorporates by reference Items 6, 7, 7A, 8 and 9 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC. Except to the extent that we specifically incorporate information by reference, our Annual Report on Form 10-K does not constitute a part of this Proxy Statement and is not incorporated by reference into this Proxy Statement.

## **Cost and Method of Solicitation**

We will pay the cost of soliciting proxies and may make arrangements with brokerage houses, custodians, nominees and other fiduciaries to send proxy materials to beneficial owners of our ordinary shares. We will reimburse these third-parties for reasonable out-of-pocket expenses. In addition to solicitation by mail, our directors, executive officers and other employees may solicit proxies by telephone, electronic transmission and personally. Our directors, executive officers and other employees will not receive compensation for such services other than regular non-employee director or employee compensation. We have retained Morrow Sodali LLC, 470 West Avenue, Stamford, Connecticut, 06902, for a fee of \$6,000, plus out-of-pocket expenses, to assist in distributing proxy materials and soliciting proxies in connection with our 2018 Annual Meeting of Shareholders.

**The information set forth in this section is, and should be construed, as a “pre-announcement notice” of the 2019 AGM in accordance with Rule 5C of the Israeli Companies Regulations (Notice of General and Class Meetings in a Public Company), 2000, as amended.**

By Order of the Board of Directors,

**Jeff Dykan**  
*Chairman of the Board of Directors*

March [\_\_\_], 2018

**Important Notice Regarding the Availability of Proxy Materials  
for the Annual Meeting of Shareholders to Be Held on April 30, 2018:**

The Notice and Proxy Statement and the 2017 Annual Report are available at <http://ir.rewalk.com/>.

**REWALK ROBOTICS LTD.**

**PROXY FOR AN ANNUAL MEETING OF SHAREHOLDERS**

**TO BE HELD ON APRIL 30, 2018**

**THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS (“BOARD”)**

The undersigned hereby constitute(s) and appoint(s) Jeff Dykan, Larry Jasinski and Ori Gon and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote, as designated on the reverse side of this proxy, on behalf of the undersigned, all of the ordinary shares, par value NIS 0.01 per share, of ReWalk Robotics Ltd. (the **“Company”**) that the undersigned is/are entitled to vote at the close of business on March 21, 2018, at the Annual Meeting of Shareholders of the Company (the **“Meeting”**) to be held at the law offices of Goldfarb Seligman & Co., Ampa Tower, 98 Yigal Alon Street, 36th floor, Tel Aviv, Israel, on April 30, 2018 at 5:00 p.m. (Israel time), and at any and all adjournments or postponements thereof on the following matters, which are more fully described in the Notice of 2018 Annual Meeting of Shareholders (the **“Notice”**) and Proxy Statement relating to the Meeting (the **“Proxy Statement”**).

**This proxy, if properly executed and received 24 hours before the Meeting, will be voted in the manner directed herein by the undersigned. If no instructions are indicated with respect to a specific proposal or all proposals described below, this proxy will be voted “FOR” each proposal. Should any other matter requiring a vote of shareholders arise, the proxies named above are authorized to vote in accordance with their discretion. Any and all proxies given by the undersigned prior to this proxy are hereby revoked.**

**(Continued and to be signed on the reverse side.)**



**ANNUAL GENERAL MEETING OF SHAREHOLDERS OF**

**REWALK ROBOTICS LTD.**

**April 30, 2018, 5:00 p.m. (Israel time)**

Please mark, sign, date and mail your proxy card in the envelope provided as soon as possible.

Please detach along perforated line and mail in the envelope provided.

**THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE “FOR” THE FOLLOWING PROPOSALS.**

**PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE:**

FOR AGAINST ABSTAIN

- 1.a. To reelect Jeff Dykan as a Class I director of the board of directors (the “Board”) of the Company.
- 1.b. To reelect Yasushi Ichiki as a Class I director of the Board of the Company.
- 1.c. To reelect Peter Wehrly as a Class I director of the Board of the Company.
2. To approve the grant of restricted share units to directors of the Board, at the time each director joins the Board and thereafter on an annual basis, in lieu of

the Company's current director equity compensation arrangements.

3. To approve the issuance of 16,000,000 ordinary shares, par value NIS 0.01 per share, in a private placement to Timwell Corporation Limited ("Timwell"), subject to the satisfaction of conditions precedent specified in the Investment Agreement between the Company and Timwell.

To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31,

4. 2018 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.

In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.

The undersigned acknowledges receipt of the Notice and Proxy Statement of the Company relating to the Annual Meeting.

To change the address on your account, please check the box at the right and indicate your new address in the space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

Signature of Shareholder    Date    Signature of Shareholder    Date

Please sign exactly as your name or names appear on this Proxy. All holders must sign. When shares are held jointly, the senior of the joint holders must sign. When signing as executor, administrator, attorney, trustee,

Note: guardian or other fiduciary, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.